[
    {
        "parameters": {
            "embedding model": "BAAI/bge-small-en-v1.5",
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 256,
            "overlap": 25,
            "top_k": 5,
            "max new tokens": 100,
            "re-ranking": 0,
            "top_n": 0
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the studies evaluating quinolones as a treatment option for 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "The studies found limited evidence on targeted quinolone therapy for 3GCephRE BSI, with one study reporting an association between quinolone treatment and lower mortality, but the analysis was limited by small sample sizes and potential biases, and therefore, there is no direct evidence to support the use of quinolones for targeted therapy.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-resistant Enterobacterales, or 3GCephrasporin-resistant K. pneumoniae, 3GCephraspor",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized",
                "Several studies have evaluated the use of quinolones as a treatment option for 3rd generation cephalosporin-resistant bloodstream infections (3GCephRE BSIs). Here are some key findings from these studies:\n\n1. Quinolones are effective against 3GCephRE BSIs caused by common pathogens such as Enterococcus faecium, Pseudomonas aeruginosa, and Klebsiella pneum",
                "Several studies have compared the effectiveness and safety of cephamycins (cefotetan and ceftriaxone), cefepime, and carbapenems (imipenem and meropenem) for the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase producing Enterobacteriaceae (3GCephre).\n\nA systematic review and meta-analysis of 12 randomized controlled trials (",
                "Several randomized controlled trials (RCTs) have evaluated the effectiveness of various antibiotics for the treatment of intra-abdominal infections (IAIs) caused by third-generation cephalosporin-resistant Enterobacterales (3GCRE). Here are some key findings from these studies:\n\n1. Carbapenems: Carbapenems, such as imipenem, meropenem, and ertapen",
                "Meropenem-vaborbactam (MVB) is a carbapenem-beta-lactamase inhibitor combination antibiotic that has shown activity against certain carbapenem-resistant Enterobacterales (CRE), including those producing NDM-1 and OXA-48-type carbapenemases. The advantage of MVB over best available treatment for susceptible CRE is supported by several studies with varying levels of evidence",
                "The comparative effectiveness and safety of aminoglycosides versus tigecycline for the treatment of complicated urinary tract infections (cUTI), including uncomplicated cUTI, have been studied in several randomized controlled trials (RCTs) and meta-analyses.\n\nA systematic review and meta-analysis of 11 RCTs involving 3,512 patients published in the Cochrane Database of Systematic Reviews in",
                "Plazomicin and colistin are both antibiotics used in the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), but the evidence comparing the two drugs in terms of efficacy, safety, and optimal use is still evolving.\n\nPlazomicin is a new generation aminoglycoside with improved activity against CRE compared to older aminoglycosides. A phase 3 clinical trial,",
                "Several studies have investigated the difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with infections caused by Carbapenem-resistant Enterobacterales (CRE), including those caused by Klebsiella pneumoniae and other Enterobacterales. The results of these studies have been inconsistent.\n\nSome studies have reported no significant difference in 28-day mortality",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE), including Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is still emerging, and the optimal approach is not yet fully established.",
                "I apologize for any confusion, but I cannot provide you with the specific results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections as there seems to be no published study with that exact title and inclusion criteria.\n\nHowever, there have been several studies investigating the effectiveness and safety of ceft",
                "CRPA (Carbapenem-resistant Pseudomonas aeruginosa) infections can be challenging to treat due to the resistance of the bacteria to many antibiotics. Polymyxins, aminoglycosides, and fosfomycin are commonly used antibiotics for the treatment of CRPA infections.\n\nPolymyxins, such as polymyxin B and E, are considered the first-line antibiot",
                "For patients with CRAB (Clostridioides difficile-related complications, including severe colitis, fulminant colitis, toxic megacolon, and sepsis) who are susceptible to sulbactam and have healthcare-associated pneumonia (HAP) or ventilator-associated pneumonia (VAP), the suggested treatment may depend on the severity of the infection and the patient's overall condition.\n\nFirst",
                "Cefiderocol is a siderophore cephalosporin antibiotic that is approved for the treatment of complicated intra-abdominal infections, including those caused by susceptible Gram-negative bacteria. CRAB (community-acquired or nosocomial acquisition, recurrent or persistent, intra-abdominal infections) is a specific type of intra-abdominal infection.\n\nSeveral studies have evaluated the effic",
                "Polymyxin-carbapenem combination therapy has been studied as a potential treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections based on the synergistic effect of both antibiotics. However, the evidence from observational studies on the effectiveness of this combination therapy is limited and often inconsistent.\n\nOne study published in the Journal of Antimicrobial Chemotherapy in 201",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections are a significant challenge in clinical microbiology due to the increasing resistance of these bacteria to commonly used antibiotics. Here are some general principles for antibiotic treatment in patients with CR-GNB infections:\n\n1. Identify the specific CR-GNB causing the infection through microbiological culture and susceptibility testing. This information is crucial for selecting the most effective antibi",
                "Patients undergoing colorectal and liver transplant surgery require careful preoperative evaluation due to the complex nature of these procedures and the potential for complications. Here are some suggested screening approaches for these patients:\n\n1. Colorectal Transplant Surgery:\n- Preoperative assessment should include a thorough history and physical examination, with a focus on the gastrointestinal system.\n- Laboratory tests: Complete blood count, coagulation studies, electro",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Resistive-Escherichia coli (ESCR-E) undergoing colorectal surgery is not well-defined due to a lack of clear consensus in the literature. However, some guidelines suggest considering PAP based on the risk of surgical site infection (SSI) and the specific characteristics of the patient and the organ",
                "Extensively drug-resistant Enterococci (ESCR-E) and extensively drug-resistant Pseudomonas aeruginosa (ESCR-PA) are bacteria that have developed resistance to most or all available antibiotics. The treatment of infections caused by these bacteria is a challenge, and the use of last-resort antibiotics should be reserved for specific cases.\n\nThe European Society of Clinical Microbiology and Infectious Dise",
                "Research protocols investigating the impact of targeted PAP (pneumococcal and other encapsulated bacteria prevention using antibiotics) in reducing post-transplant infections among Extended-Spectrum Cephalosporin Resistant-Enterococcus (ESCR-E) colonized Solid Organ Transplant (SOT) candidates should include the following elements:\n\n1. Study Design: Clearly define the study design, including the type of study (",
                "Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. The goal of PAP is to reduce the risk of surgical site infections (SSIs). In patients colonized with CRE, the risk of developing SSIs is increased due to the potential for carrying antibiotic-resistant bacteria. Therefore, targeted",
                "Screening SOT (solid organ transplant) recipients for CRAB (chronic rejection, acute rejection, banff lesions) before surgery involves a comprehensive evaluation to assess the current status of the transplanted organ and the overall health of the recipient. Here are some good practices for screening SOT recipients for CRAB before surgery:\n\n1. Review of medical history: A thorough review of the recipient's medical history, including details of the transplant procedure",
                "To investigate CRAB (Candida auris-related bloodstream infections) colonization and targeted PAP (positive blood culture identification and antimicrobial stewardship), the following types of clinical trials could be suggested:\n\n1. Prospective observational studies: These studies can be used to assess the prevalence and incidence of CRAB colonization in different patient populations and settings. They can also evaluate the effectiveness of targeted PAP in identifying CRAB in",
                "In transplant surgery other than renal transplants, the suggested duration of post-anesthesia care unit (PACU) or post-operative recovery varies depending on the specific type of transplant and the individual patient's condition. Here are some general guidelines for different types of transplants:\n\n1. Liver transplant: Patients typically stay in the PACU for 1-2 days after the surgery. However, some patients may require a longer",
                "MDR-GNB (Multidrug-resistant Gram-negative bacteria) infections are a significant concern in solid organ transplant (SOT) recipients due to their increased susceptibility to infections and the potential for antibiotic resistance. The risk of MDR-GNB infections in SOT recipients varies depending on several factors, including the type of transplant, the underlying condition of the patient, and the exposure to healthcare environments.\n\nAccording to a",
                "The identification of fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is important to reduce the risk of post-biopsy infections and potential development of antibiotic-resistant bacteria. Here are some suggested approaches to identify FQR-E carriers:\n\n1. Pre-biopsy urine culture: Ob",
                "A randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (Prostate Antigen Percentage using ciprofloxacin as a urinary selective inhibitor of bacterial growth) and culture-based PSA (Prostate Specific Antigen) in patients undergoing Transrectal Ultrasound-Guided Prostate Biopsy (TRUSPB) would provide data on the diagnostic accuracy and utility",
                "Urinary colonization with MDR-GNB has been identified as a risk factor for postoperative infections in patients undergoing urologic surgery. The presence of MDR-GNB in the urine before surgery increases the likelihood of developing postoperative infections, particularly urinary tract infections (UTIs).\n\nStudies have shown that the incidence of urinary colonization with MDR-GNB is higher in patients undergoing urologic surgery compared to",
                "Reducing surgical site infections (SSIs) requires a comprehensive approach that addresses various factors before, during, and after surgery. Here are some key elements of a comprehensive approach to reducing SSIs:\n\n1. Preoperative preparation:\n   a. Proper patient selection and optimization\n   b. Timely and appropriate antibiotic prophylaxis\n   c. Controlling risk factors such as diabetes, obesity, and malnutrition\n   d.",
                "Standard Operating Procedures (SOPs) for sampling site techniques and microbiological methods are essential to ensure consistency, accuracy, and reliability of data obtained from environmental or laboratory investigations. Here are some recommended practices for developing SOPs in these areas:\n\n1. Sampling Site Techniques:\n\na. Define the sampling objectives, location, and frequency.\nb. Establish a chain of custody for samples to maintain their integrity from the time of collection to",
                "When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered to optimize the effectiveness of the antibiotic prophylaxis and minimize the risk of selecting for antibiotic resistance or causing adverse effects. Some of these factors include:\n\n1. Timing of administration: PAP should be administered within one hour before the surg",
                "Colonization status refers to the presence of potentially harmful bacteria in the body, particularly in the gastrointestinal tract, that do not cause infection in a healthy individual but can cause infections after a solid organ transplantation (SOT). These infections, known as translocation infections, can lead to significant morbidity and mortality in transplant recipients.\n\nThe importance of knowing the colonization status of a patient before SOT lies in the fact that certain"
            ],
            "additional prompt / no context": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum \u03b2-lactamase producing Klebsiella pneumoniae (3GCephrasporin-resistant, or 3GCephrE), the recommended targeted therapy is usually a carbapenem antibiotic, such as meropenem or imipenem. Other options may include polymyxins or aminocoumarins,",
                "The evidence on the treatment of infections caused by third-generation cephalosporin-resistant bacteria (3GCRE) is organized through numerous studies, meta-analyses, and guidelines. These sources provide evidence on the effectiveness and safety of various antibiotics, including carbapenems, aminoglycosides, and polymyxins, among others. The Infectious Diseases Society of America (IDSA) and European Society of Clin",
                "Quinolones have shown effectiveness in treating 3GCephalosporin-resistant bloodstream infections (BSIs). However, resistance to quinolones is increasing, so their use should be reserved for infections caused by susceptible bacteria. Adverse effects, including peripheral neuropathy and tendinitis, should be monitored closely.",
                "The studies suggest that cephamycins and cefepime are comparable to carbapenems in terms of clinical cure rates for pyelonephritis caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). However, higher resistance rates to cephamycins and cefepime may require larger doses or alternative agents.",
                "The RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3rd-generation cephalosporin-resistant (3GCephR) bacteria have shown that:\n\n1. Carbapenems (imipenem, meropenem) are effective in treating 3GCephR-IAI.\n2. Aminoglycosides (gentamicin,",
                "The level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible Carbapenem-resistant Enterobacterales (CRE) is high, based on numerous randomized controlled trials and meta-analyses demonstrating superior clinical response and microbiological eradication rates.",
                "The evidence for the advantage of aminoglycosides over tigecycline for complicated urinary tract infections (cUTI) is inconclusive. Some studies suggest that aminoglycosides may have similar efficacy to tigecycline, while others suggest that tigecycline may have a slightly better safety profile. Ultimately, the choice between these antibiotics depends on individual patient factors and clinician preference.",
                "Plazomicin, a new antibiotic, has shown promise in clinical trials for the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), including those that are resistant to colistin. However, more data from larger, randomized controlled trials are needed to definitively establish the superiority of plazomicin over colistin in terms of clinical outcomes, safety, and resistance development. Therefore, the evidence is not yet sufficient",
                "Yes, there are studies suggesting that colistin-carbapenem combination therapy may have a lower 28-day mortality rate compared to colistin monotherapy in patients with Carbapenem-resistant Enterobacteriaceae (CRE) infections. However, the evidence is not definitive, and more research is needed to confirm these findings. It's important to note that individual patient outcomes can vary significantly based on factors such as underlying health conditions and",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE). The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections comes from several clinical studies.\n\nA randomized controlled trial (RCT) by Bekas et al. (2019) showed that monotherapy with cefiderocol led to similar",
                "The retrospective cohort study found that ceftolozane-tazobactam was associated with a higher clinical cure rate (83.3%) compared to polymyxins or aminoglycosides (63.6%) in patients with MDR/XDR P. aeruginosa mixed infections. However, it's important to note that retrospective studies have limitations, and more well-designed studies are needed to confirm these",
                "For severe infections caused by CRPA (Carbapenem-resistant Pseudomonas aeruginosa), the recommended antibiotic regimens include:\n\n1. Polymyxins (e.g., polymyxin B or E) in combination with an aminoglycoside (e.g., gentamicin or tobramycin).\n2. Monotherapy with a newer polymyxin (e.g",
                "For patients with CRAB (Carbapenem-resistant Acinetobacter baumannii) and susceptible to sulbactam but resistant to other antibiotics in the setting of HAP (Healthcare-associated pneumonia) or VAP (Ventilator-associated pneumonia), the suggested treatment options may include:\n\n1. Polymyxins (e.g., colistin or polymyxin",
                "Cefiderocol is an antibiotic with activity against gram-negative bacteria, including those commonly responsible for CRAB (community-acquired or healthcare-associated carbapenem-resistant acinetobacter baumannii) infections. Several studies have shown that cefiderocol is effective in treating CRAB infections, with success rates similar to or superior to other antibiotics such as colistin and tigecycline. However, it",
                "Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB (Carbapenem-resistant Acinetobacter baumannii) infections. However, high-quality randomized controlled trials are needed to provide stronger evidence of its efficacy and safety. The combination therapy may improve outcomes by synergistic effects of both antibiotics against carbapenem-resistant A. baumannii.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections require specific antibiotic treatment due to their resistance to commonly used antibiotics. Here are some general principles for antibiotic treatment:\n\n1. Identify the specific CR-GNB causing the infection through laboratory testing.\n2. Choose an antibiotic that is active against the identified CR-GNB.\n3. Consider the site of infection, severity, and patient",
                "For patients undergoing colorectal transplant surgery, preoperative screening typically includes colonoscopy to assess for colon cancer or precancerous lesions. For liver transplant patients, screening may include hepatitis serology, imaging studies like ultrasound or CT scan, and tumor markers like AFP. The specific screening approach may vary depending on individual patient risk factors and transplant type. Always consult with a healthcare professional for personalized medical advice.",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Cephalosporin-Resistant Enterococci (ESCR-E) undergoing colorectal surgery is controversial. Some guidelines suggest considering alternative antibiotics for PAP, while others recommend using a different class of antibiotics altogether, such as aminoglycosides or glycopeptides. Ultimately",
                "The antibiotics that should be reserved for the treatment of extensively resistant bacteria (such as extensively drug-resistant Mycobacterium tuberculosis or carbapenem-resistant Enterobacteriaceae) include:\n\n1. Polymyxins (e.g., colistin)\n2. Aminoglycosides (e.g., amikacin, gentamicin)\n3. Tigecycline",
                "Recommended components for research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates include:\n\n1. Study design: Randomized controlled trials (RCTs) or observational studies.\n2. Study population: ESCR-E colonized SOT candidates.\n3. Intervention: Targeted PAP (pre-transplant antimicrobial prophylaxis)",
                "Yes, a recommendation can be issued for targeted PAP for patients colonized with CRE before surgery to reduce the risk of surgical site infections caused by these bacteria. However, the specific antibiotic choice should be based on local resistance patterns and potential for cross-resistance. Consult local guidelines and infectious disease specialists for the most appropriate antibiotic selection.",
                "A good practice for screening Solid Organ Transplant (SOT) recipients for CRAB (Chronic Renal Allograft Abolition) before surgery is to assess their renal function with regular serum creatinine levels and estimated glomerular filtration rate (eGFR). Additionally, monitoring for proteinuria, hematuria, and signs of allograft dysfunction is essential. If there are concerns, a renal biopsy may be necessary",
                "To investigate CRAB (Clostridioides difficile-related antibiotic-associated bacterial) colonization and targeted PAP (phage-based antibiotic prophylaxis), the panel would suggest designing randomized controlled trials (RCTs) with a placebo or active comparator arm. These trials should include adequate sample size, proper power analysis, and appropriate endpoints to assess the efficacy and safety of targeted PAP in preventing CRAB colon",
                "In transplant surgery other than renal transplant, the suggested duration of post-operative positive airway pressure (PAP) varies depending on the specific type of transplant and individual patient's condition. Generally, it ranges from a few days to several weeks. For example, in liver transplant, PAP may be used for a few days to help prevent respiratory complications. In heart-lung transplant, PAP may be required for several weeks to help the",
                "The risk of Multidrug-resistant Gram-negative bacterial (MDR-GNB) infections in solid organ transplant (SOT) recipients is relatively high due to the use of immunosuppressive medications. These infections can lead to serious complications such as sepsis, organ failure, and increased mortality. Common MDR-GNB pathogens include P. aeruginosa, Acinetobacter baumannii, and Kle",
                "The suggested approach to identify FQR-E carriers before TRUSPB includes:\n\n1. Obtaining a urine culture before the procedure.\n2. Sensitivity testing for fluoroquinolones in the urine culture result.\n3. Considering alternative antibiotics for prophylaxis if FQR-E is identified.\n\nIt's important to note that the decision to test for FQR-E should be based on local",
                "The specific outcome of the trial you're referring to is not readily available in a clear and short answer format, as I would need to access the study's results to provide an accurate response. However, in general, non-blinded trials may be subject to bias, and comparing ciprofloxacin PAP (prostate antimicrobial prostatease) to culture-based PAP (transrectal ultrasound-guided prostate bi",
                "Urinary colonization with MDR-GNB is a significant risk factor for postoperative infections in patients undergoing urologic surgery. These bacteria can cause infections during or after the procedure, leading to increased morbidity and mortality. Preoperative urine screening and appropriate antibiotic prophylaxis can help reduce the risk of these infections.",
                "A comprehensive approach to reducing surgical site infections (SSIs) includes:\n\n1. Preoperative preparation: Optimizing the patient's health, proper wound preparation, and prophylactic antibiotics.\n2. Intraoperative measures: Sterile environment, proper surgical technique, and use of sterile instruments.\n3. Postoperative care: Wound care, early ambulation, and appropriate use of drains and dressings.\n4.",
                "For standard operating procedures (SOPs) related to sampling site technique, it's important to follow these steps:\n\n1. Properly clean and prepare the sampling site.\n2. Use sterile equipment for sampling.\n3. Collect sufficient sample size.\n4. Transport samples to the lab in appropriate containers and at proper temperature.\n\nFor microbiological methods, SOPs should include:\n\n1. Properly handling and transporting samples.",
                "When choosing targeted PAP for CRE infections, consider the following factors:\n\n1. Type and location of the surgery: The risk of surgical site infection (SSI) varies depending on the type and location of the surgery.\n2. Patient risk factors: Factors such as age, comorbidities, and underlying conditions increase the risk of SSIs.\n3. Type and susceptibility of the CRE isolate: The specific type and susceptibility of",
                "Colonization of a patient with bacteria or other pathogens that can cause infections is important to consider before solid organ transplantation (SOT) because these infections can lead to graft failure, increased morbidity, and mortality. Immunosuppressive drugs used after transplantation can weaken the patient's immune system, making them more susceptible to infections. Knowing the colonization status allows healthcare providers to take appropriate measures to prevent or treat"
            ],
            "no additional prompt / context": [
                "Based on the context provided, the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE is a carbapenem (imipenem or meropenem) (strong recommendation for use, moderate certainty of evidence).",
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including Bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infections (IAI). For BSI, the MERINO trial compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-res",
                "The studies evaluating quinolones as a treatment option for 3GCephRE BSI were observational in design and the quinolone group was very small in all studies. There is no direct evidence on targeted quinolone therapy for 3GcephRE BSI, but favorable effects were observed in studies assessing Gram-negative bacteriaemia in general. However, given the paucity of data and observational design, there is very-low-",
                "None of the retrospective cohort studies found statistically significant differences between cephamycins and cefepime, and carbapenems for the treatment of pyelonephritis caused by 3GCephRE. All studies were at high risk of bias, and the sample sizes were very small, providing low-certainty evidence for the use of cephamycins and cefepime in this context.",
                "The MERINO trial was a randomized controlled trial (RCT) that compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant Escherichia coli and K. pneumoniae. The study found that meropenem was non-inferior to piperacillin-tazobactam in terms of clinical cure and micro",
                "Based on the small RCT (Tango-II) study mentioned in the context, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics. However, it is important to note that the sample size was small, and more research is needed to confirm these findings.",
                "The certainty of the evidence for an advantage of aminoglycosides over tigecycline for cUTI is moderate. The evidence includes studies that have shown higher survival rates with aminoglycosides compared with non-aminoglycoside regimens in patients with carbapenem and colistin-resistant K. pneumoniae with a prevalent respiratory source [127]. Another study observed better clinical cure with amin",
                "Based on the context provided, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The CRaCKle cohort study showed all-cause mortality at 28 days was lower with plazomicin combination therapy compared to colistin combination therapy, but the study was suspended after 2 years and there is currently not enough data to make a definitive conclusion.",
                "Based on the available evidence from the AIDA and OVERCOME trials, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections [160, 179]. However, it is important to note that these trials included mostly patients with CRAB infections, and the results may not be generalizable to all types of CRE",
                "Based on the available evidence, there is low-certainty evidence for the non-inferiority of cefercol monotherapy compared to other antibiotics for MBL-producing CRE infections. A subgroup analysis of patients with MBL-producing CR-GNB infections showed statistically non-significant higher cure and microbiological eradication rates for cefercol, but there was no significant difference in mortality. However, a post",
                "The retrospective cohort study compared the outcomes of 100 patients treated with ceftolozane-tazobactam and 100 patients treated with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections. The study found that clinical care was higher (adjusted OR 2.63, 95% CI 1.31-5.3",
                "Based on the available evidence, it is recommended to treat severe infections caused by CRPA with two in vitro active drugs when using polymyxins, aminoglycosides, or fosfomycin (conditional recommendation for use, very low certainty of evidence). No specific combination recommendations can be provided.",
                "Based on the context provided, for patients with CRAB susceptible to sublactam and HAP/VAP, we suggest ampicillin-sublactam as the antibiotic of choice (conditional recommendation, low certainty of evidence).",
                "Based on the available evidence, the clinical and microbiological efficacies of cefiderocol versus other antibiotics in treating CRAB infections are similar. However, a subgroup analysis of patients with MBL-producing CRE infections showed statistically non-significant higher cure and microbiological eradication rates for cefiderocol, but the difference in mortality was not significant. The analysis did not separate CRE from other CR-GNB.",
                "Several observational studies have assessed the combination of polymyxins and carbapenems for CRAB infections, but the results are inconsistent. Some studies showed a significant association between the use of the combination and survival or clinical cure [198, 235, 247], while others did not [199, 244]. However, many of these studies included patients treated with a polymyxin-carbapen",
                "1. Antibiotic stewardship considerations are important when choosing antibiotics for CR-GNB infections, especially for last-resort antibiotics like colistin and new BLBLI.\n2. The current guidelines recommend targeting specific pathogens with appropriate antibiotics, especially for patients considered at high risk for CR-GNB infections during the empirical treatment phase.\n3. For CR-GNB that are resistant to all b",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery, according to the local epidemiology. This is a conditional recommendation with low certainty of evidence. It might also be a good practice to screen all SOT recipients for ESCR-E before surgery, according to the",
                "Based on the evidence presented in the context, a conditional recommendation for use of targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery is made, with a low certainty of evidence. This recommendation is based on two studies, one of which was a multicenter, non-randomized, non-blinded interventional study that showed a potential benefit of etapenem use in reducing postoperative infections in ESCR",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. The",
                "1. Postsurgical monitoring of antibiotic resistance: This includes conducting rectal cultures for CRE colonization, especially if carbapenem-based PAP is used.\n        2. Reporting antimicrobial susceptibility: Researchers should report antimicrobial susceptibility results according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines.\n        3. Trial design considerations: The trial design",
                "Based on the current evidence, no definitive recommendation can be issued for or against targeted PAP for patients who are colonized with CRE before surgery. The available evidence is limited, and there is a need for well-designed clinical trials to evaluate the effectiveness, applicability, and safety of targeted PAP in CRE carriers undergoing high-risk surgical procedures, such as transplant surgery. These trials should consider rectal culture results, the limited number of options for treating",
                "It might be a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology (ungraded good practice statement). Any change in procedures should follow a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards, considering a prevalence >=10% as a cut-off for implementation evaluation (based on previous recommendation). The choice of targeted versus universal screening should be based on the local work",
                "The panel suggests designing clinical trials to investigate the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in clinical trials. These trials should consider rectal culture results, the limited number of options for treating CRE infections, and resistance monitoring to detect emerging resistance to the regimens used for targeted PAP.",
                "Based on the context provided, the suggested duration of PAP in transplant surgery other than renal transplant is 48-72 hours, according to some expert recommendations. However, it is important to note that there is currently no formal consensus on PAP duration in transplant surgery beyond renal transplant, and further research is needed to investigate the clinical impact of shorter versus longer PAP durations. Additionally, the duration of targeted PAP should align with current recommendations by international societies",
                "The risk of MDR-GNB infections in solid organ transplant (SOT) recipients varies depending on the type of organ transplanted and the geographic area. According to available data, SSIs are a common issue in SOT recipients, with highest rates observed for intestinal, liver, and pancreas transplantation. Intra-abdominal infections, especially in the early post-transplant period, are a significant concern for liver trans",
                "Based on the context provided, it is recommended to perform rectal screening to identify FQR-E carriers before TRUSPB. This is a conditional recommendation with moderate certainty of evidence.",
                "The randomized, non-blinded, multicenter trial compared ciprofloxacin PAP versus culture-based PAP in 1288 patients undergoing TRUSPB, including 15.8% FQR carriers. The study showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB",
                "The evidence suggests that patients with urinary colonization with MDR-GNB have a higher risk of postoperative infections, particularly SSIs, compared to noncolonized patients undergoing urologic surgery. However, studies directly comparing postoperative infections in MDR-GNB urinary carriers versus noncarriers are lacking. A small, prospective single-centre study reported that 15% of postoperative infections in patients receiving targeted PAP based",
                "The comprehensive approach required to reduce surgical site infections (SSIs) involves a combination of antibiotic-based interventions and best surgical practices. Antibiotic-based interventions include targeted preoperative antibiotic prophylaxis (PAP) for MDR Gram-negative bacteria (MDR-GNB) carriers, especially in areas with high burden and for high-risk surgery. Additionally, optimizing antibiotic stewardship initiatives is essential",
                "Based on the context provided, there is a recommendation for implementing rectal screening to identify Carbapenem-resistant Acinetobacter baumannii (CRAB) carriers before liver transplant surgery according to local epidemiology (conditional recommendation, low certainty of evidence). The choice of targeted versus universal screening should be based on local work organization and integrated within antibiotic and diagnostic stewardship guidance. Irrespective of the PAP, the knowledge of the",
                "1. Consider the local epidemiology of CRE infections and the incidence of CRE SSIs in your institution.\n2. The choice of targeted PAP should take into consideration the limited number of options available for the treatment of CRE infections, avoiding novel compounds that may be required for the treatment of postsurgical infections.\n3. Resistance monitoring should be performed through detection of MDR-CRE carriage after surgery and to detect emerging resistance to the regim",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) because MDR-GNB (multidrug-resistant gram-negative bacteria) colonization has been associated with increased rates of postoperative infections and SSIs (surgical site infections) in SOT patients. Early detection of MDR-GNB carriers can inform contact precautions in SOT candidates and may be useful in guiding the treatment of"
            ],
            "additional prompt / context": [
                "A carbapenem (imipenem or meropenem) is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE (strong recommendation for use, moderate certainty of evidence).",
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including Bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infections (IAI). For BSI, the MERINO trial compared piperacillin-tazobactam with meropenem, but most studies showed no significant difference between groups. Observational data shows no differences in mort",
                "The studies evaluating quinolones as a treatment option for 3GCephRE BSI were observational in design and the quinolone group was very small in all studies. There is no direct evidence on targeted quinolone therapy for 3GcephRE BSI, but favorable effects were observed in studies assessing Gram-negative bacteriaemia in general. However, given the paucity of data and observational design, there is very-low-",
                "None of the retrospective cohort studies found statistically significant differences between cephamycins and cefepime, and carbapenems for the treatment of pyelonephritis caused by 3GCephRE. All studies were at high risk of bias, and the evidence provided low-certainty for the use of cephamycins and cefepime for this indication.",
                "The MERINO trial was a randomized controlled trial (RCT) that compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant E. coli and K. pneumoniae. The study found that meropenem was non-inferior to piperacillin-tazobactam in terms of clinical cure and microbiological er",
                "Based on the small RCT (Tango-II) study, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics.",
                "The certainty of the evidence for an advantage of aminoglycosides over tigecycline for cUTI is moderate.",
                "Based on the context provided, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The CRaCKle cohort study showed all-cause mortality at 28 days was lower with plazomicin combination therapy compared to colistin combination therapy, but the study was suspended after 2 years due to enrolment difficulties and there is currently insufficient evidence on plazomic",
                "Based on the available evidence from the AIDA and OVERCOME trials, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. (Moderate-certainty evidence)",
                "Based on the available evidence, there is low-certainty evidence for the non-inferiority of cefiderocol compared to other antibiotics for MBL-producing CRE infections. However, there is no clear evidence to recommend for or against the use of combination therapy with cefiderocol for CRE infections. The evidence is conflicting regarding the use of combination therapy versus monotherapy for CRE infections overall, with some studies suggesting better clinical outcomes",
                "The retrospective cohort study reported higher clinical care (adjusted OR 2.63, 95% CI 1.31-5.30) and lower nephrotoxicity (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam compared with polymyxins or aminoglycosides",
                "We recommend treating severe infections caused by CRPA with two in vitro active drugs when using polymyxins, aminoglycosides, or fosfomycin (conditional recommendation, very low certainty of evidence). No specific combination recommendations can be provided.",
                "Based on the context provided, for patients with CRAB susceptible to sulbactam and HAP/VAP, we suggest ampicillin-sublactam as the antibiotic of choice (conditional recommendation, low certainty of evidence).",
                "Based on the available evidence, we conclude on low-certainty evidence for the non-inferiority of cefiderocol compared to other antibiotics for MBL-producing CRE infections. However, there is limited information available to date, and we cannot make a definitive recommendation for or against the use of cefiderocol for CRAB infections.",
                "Several observational studies have shown an association between the use of polymyxin-carbapenem combinations and improved survival or clinical cure in CRAB infections. However, not all studies have reported positive results, and it's important to note that many of these studies included patients treated with various combination therapies, making it difficult to assess the specific effects of a polymyxin-carbapenem combination. High-certainty evidence against the use of",
                "1. Antibiotic stewardship considerations are important in the treatment of CR-GNB infections.\n2. The current guidelines recommend targeting specific pathogens with appropriate antibiotics based on local epidemiology during the empirical treatment phase.\n3. For CR-GNB that are resistant to all b-lactams, testing against new BLBLI and polymyxins is recommended.\n4. Follow-up cultures are recommended in",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epidemiology (",
                "We conditionally recommend targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery. This recommendation is based on low certainty of evidence from two studies, one of which was a multicenter study showing a potential benefit of etapenem use in reducing postoperative infections in ESCR-E carriers [41]. However, it is important to note that there is a need for well-designed RCTs to provide more",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. Car",
                "1. Postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n3. Designing clinical trials in ESCR-E carriers undergoing high-risk surgical procedures, considering the local",
                "Based on the current evidence, no definitive recommendation can be issued for or against targeted PAP for patients who are colonized with CRE before surgery. However, it is recommended to design clinical trials to assess the impact of CRE rectal screening in high-risk surgeries, including the effectiveness, applicability, and safety of targeted PAP following antimicrobial stewardship principles. These trials should consider rectal culture results, the limited number of options for treating C",
                "It is a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology (ungraded good practice statement). Any change in procedures should follow a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards, considering a prevalence >=10% as a cut-off for implementation evaluation (previous recommendation). The choice of targeted versus universal screening should be based on the local work organization and integrated",
                "1. Clinical trials comparing the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery.\n        2. Clinical trials investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
                "Based on current recommendations from IDSA/ASHP/SIS/SHEA and other international societies, PAP should be discontinued within 24 hours after surgery in patients colonized with MDR-GNB for transplant surgery other than renal transplant as well. However, in some cases, extending PAP duration to 48-72 hours may be considered according to the type of transplant. Further research is needed to investigate the clinical impact of shorter versus",
                "The risk of MDR-GNB infections in SOT recipients ranges from 3% to 53%, with the highest rates observed for intestinal, liver, and pancreas transplantation. Intra-abdominal infections, particularly in the early post-transplant period, are common in liver transplant recipients, with a risk of ESBL and CRKP infections ranging from 6% to 13% and 3%",
                "We suggest rectal screening to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
                "The trial reported a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for patients receiving culture-based PAP compared to ciprofloxacin PAP. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers. However, the study was not",
                "There is evidence suggesting an association between urinary colonization with MDR-GNB and postoperative infections in patients undergoing urologic surgery. However, further research is needed to identify the impact of MDR-GNB colonization and targeted preoperative antibiotic prophylaxis (PAP) based on preoperative cultures on postoperative infections. The optimal targeted PAP for different MDR-GNB should also be investigated according to the type of",
                "A comprehensive approach to reduce SSIs requires a focus on both antibiotic-based interventions and best surgical practices. This includes minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, and managing patient comorbidities. Additionally, heightening stewardship initiatives to monitor and contain the consequences of new prescription patterns, enhance surveillance protocols, improve local adherence to guidelines, and promote a multidisciplinary approach are essential",
                "1. It is recommended to consider rectal culture results for clinical trials of targeted PAP for CRE carriers undergoing surgery.\n2. The choice of targeted PAP should take into consideration the limited number of options available for the treatment of CRE infections, avoiding novel compounds that may be required for the treatment of postsurgical infections.\n3. Resistance monitoring should be performed through detection of MDR-CNB carriage after surgery and to detect emerging resistance to the",
                "1. Limited options for treating CRE infections: The choice of targeted PAP should consider the limited number of available options for treating CRE infections.\n        2. Avoiding novel compounds: Novel compounds that may be required for the treatment of postsurgical inctions should be avoided in targeted PAP.\n        3. Rectal culture results: Clinical trials of targeted PAP should be designed considering rectal culture results.\n        4. Resistance monitoring:",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) because this information can help in the early implementation of infection control procedures to reduce the risk of intrahospital and community spreading of multidrug-resistant germs (MDR-GNB). This knowledge can also inform contact precautions and may be taken into consideration when treating postoperative infections. The choice of targeted versus universal screening for MDR-GNB colonization"
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.10426927455870987,
                    "2_gram": 0.17232945312043874,
                    "3_gram": 0.12203449066382968,
                    "4_gram": 0.08598788681468703
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.23668217296509428,
                        "recall": 0.4109030657231275,
                        "fmeasure": 0.285740394312968
                    },
                    "rouge_L": {
                        "precision": 0.15572278316466392,
                        "recall": 0.2809290035071148,
                        "fmeasure": 0.1908752053324701
                    }
                },
                "METEOR": 0.23717818182947348,
                "BERTScore": {
                    "Precision": -0.003,
                    "Recall": 0.171,
                    "F1_measure": 0.083
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.11141463788088923,
                    "2_gram": 0.18204904662284616,
                    "3_gram": 0.13031715085607568,
                    "4_gram": 0.09079129596816363
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.24730519574032211,
                        "recall": 0.4196049847717524,
                        "fmeasure": 0.2914223958282858
                    },
                    "rouge_L": {
                        "precision": 0.17372168561673687,
                        "recall": 0.2921140135388925,
                        "fmeasure": 0.2044809352091253
                    }
                },
                "METEOR": 0.2426199338470025,
                "BERTScore": {
                    "Precision": 0.04,
                    "Recall": 0.216,
                    "F1_measure": 0.127
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.12081775551668017,
                    "2_gram": 0.2220390139895074,
                    "3_gram": 0.20867658109003567,
                    "4_gram": 0.1694809780627205
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.39262081360867734,
                        "recall": 0.6952359161259993,
                        "fmeasure": 0.47839959422303074
                    },
                    "rouge_L": {
                        "precision": 0.2960652520318727,
                        "recall": 0.5417497590261967,
                        "fmeasure": 0.3659057515504738
                    }
                },
                "METEOR": 0.4743170423581453,
                "BERTScore": {
                    "Precision": 0.27,
                    "Recall": 0.514,
                    "F1_measure": 0.388
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.14450400290807006,
                    "2_gram": 0.25763571136004615,
                    "3_gram": 0.24888898472520826,
                    "4_gram": 0.20636067856850976
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.46793042650001326,
                        "recall": 0.7040450967815939,
                        "fmeasure": 0.5250444506548323
                    },
                    "rouge_L": {
                        "precision": 0.384473493932396,
                        "recall": 0.590361347722723,
                        "fmeasure": 0.43558435522879135
                    }
                },
                "METEOR": 0.5121445961781058,
                "BERTScore": {
                    "Precision": 0.358,
                    "Recall": 0.558,
                    "F1_measure": 0.454
                }
            }
        }
    },
    {
        "parameters": {
            "embedding model": "BAAI/bge-small-en-v1.5",
            "llm": "microsoft/Phi-3-mini-128k-instruct",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 256,
            "overlap": 25,
            "top_k": 5,
            "max new tokens": 100,
            "re-ranking": 0,
            "top_n": 0
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the studies evaluating quinolones as a treatment option for 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "The studies found limited evidence on targeted quinolone therapy for 3GCephRE BSI, with one study reporting an association between quinolone treatment and lower mortality, but the analysis was limited by small sample sizes and potential biases, and therefore, there is no direct evidence to support the use of quinolones for targeted therapy.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                " The question seems to be referring to a specific type of cancer treatment, but the terms \"BSI,\" \"severe infection,\" and \"3GCephRE\" are not standard in medical terminology. It's possible that there's a mix-up or abbreviation that's not widely recognized.\n\nHowever, I can provide information on targeted therapy for a common type of cancer that might be relevant to your question:\n\nTargeted therapy is a",
                " The evidence on the treatment of infections caused by 3GCephRE (presumably a typo or a specific class of bacteria) is organized in a systematic and comprehensive manner to ensure that healthcare professionals and researchers can access and utilize the information effectively. Here's an overview of how this evidence is typically organized:\n\n1. Systematic reviews and meta-analyses: These are high-level evidence sources that summarize and analyze",
                " The studies evaluating quinolones as a treatment option for patients with multidrug-resistant Gram-negative bacterial bloodstream infections (3GCephRE BSI) have shown mixed results. Some studies suggest that quinolones, particularly fluoroquinolones, can be effective against certain multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherich",
                " I'm sorry, but it seems there might be a misunderstanding or typo in the question. \"3GCephRE\" does not correspond to any known antibiotic or bacterial strain. It's possible that the intended reference was to \"E. coli\" or another bacterium commonly associated with pyelonephritis, which is a type of urinary tract infection that affects the kidneys.\n\nAssuming the question is",
                " I'm sorry, but it seems there might be a misunderstanding or typo in the question. \"3GCephRE\" does not correspond to any known antibiotic or bacterial strain. It's possible that the intended reference was to a specific antibiotic or a group of antibiotics, but without the correct name, it's challenging to provide a specific answer.\n\nHowever, I can provide a general overview of how Random",
                " The level of evidence for the advantage of meropenem-vaborbactam over the best available treatment for susceptible carbapenem-resistant Enterobacteriaceae (CRE) can be categorized based on the strength and quality of clinical research. As of my last update in 2023, the evidence primarily comes from retrospective studies, case series, and a few randomized controlled trials (RCTs).\n\n1. **",
                " The level of evidence for the advantage of aminoglycosides over tigecycline for the treatment of complicated urinary tract infections (cUTI) is not definitive and can vary based on the specific context and patient population. Clinical trials and meta-analyses are essential to determine the efficacy and safety of these antibiotics.\n\nAminoglycosides, such as gentamicin, tobramyc",
                " As of my last update in early 2023, plazomicin has been studied as a potential alternative to colistin for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections. Plazomicin is a next-generation aminoglycoside with a broader spectrum of activity and improved pharmacokinetics, which may overcome some of the limitations associated with colistin, such as ne",
                " To answer this question, a systematic review and meta-analysis of the available literature comparing the 28-day mortality rates between colistin monotherapy and colistin-carbapenem combination therapy in patients with CRE (Carbapenem-Resistant Enterobacteriaceae) infections would be required.\n\n\nA comprehensive search of databases such as PubMed, Embase, and the Cochrane Library would be conducted",
                " Cefiderocol is a siderophore cephalosporin that has been developed to treat infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections comes from clinical trials and studies that compare the efficacy, safety, and resistance development of these treatment strategies.\n\n1. Efficacy",
                " I'm sorry, but as of my last update in April 2023, I don't have access to real-time databases or the ability to retrieve or summarize specific studies or their results. To find the results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with multidrug-resistant (MDR) or extensively drug-resistant",
                " The treatment of severe infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA) with polymyxins, aminoglycosides, or fosfomycin should be approached with caution and typically involves a combination of antimicrobial agents to achieve synergistic effects and to prevent the development of further resistance.\n\n1. Polymyxins: Polymyxins, such as colistin",
                " The treatment for patients with CRAB (Calcium elevation, Renal failure, Anemia, and Bone lesions) susceptible to sulbactam and HAP/VAP (Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia) should be individualized based on the patient's specific condition, microbial susceptibility, and local antibiotic resistance patterns. However, a general approach can be suggested:",
                " Cefiderocol is a siderophore cephalosporin that has shown promising results in treating carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Its efficacy is attributed to its unique mechanism of action, which involves binding to iron and being actively transported across the bacterial outer membrane. This allows cefiderocol to penetrate the bacterial cell wall and exert",
                " As of my last update in April 2023, the combination therapy of polymyxins and carbapenems for the treatment of CRAB (Catheter-Related Bloodstream Infections) caused by multidrug-resistant organisms has been a subject of interest due to the increasing prevalence of antibiotic resistance. However, the evidence from observational studies on the effectiveness of this combination therapy is limited and somewhat mixed.",
                " The general principles for antibiotic treatment in patients with Chronic Rhinosinusitis (CRS) with nasal polyps (CR-GNB) infections are as follows:\n\n\n1. **Diagnosis and Identification**: Accurate diagnosis of CR-GNB is essential. This involves a thorough clinical evaluation, including nasal endoscopy and imaging studies like CT scans. Identification of the causative organisms through cult",
                " The suggested screening approach for patients undergoing colorectal and liver transplant surgery involves a comprehensive evaluation to assess the risk of colorectal cancer (CRC) and hepatocellular carcinoma (HCC), which are the primary cancers associated with these transplants. The screening should be tailored to the individual patient's risk factors, including age, family history, and underlying liver disease.\n\nFor colorectal",
                " The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended Spectrum \u03b2-Lactamase-producing Enterobacteriaceae (ESCR-E) undergoing colorectal surgery is to administer a third-generation cephalosporin or a carbapenem. This is due to the high risk of infection with ESCR-E organisms, which are resist",
                " The treatment of extensively drug-resistant (XDR) bacteria requires careful consideration due to the limited options available. Antibiotics reserved for the treatment of XDR bacteria and not used routinely for targeted PAP (prophylaxis against infection) in Extended Spectrum \u03b2-Lactamase (ESBL)-producing carriers (ESCR-E) are typically those with a narrow spectrum of activity and high efficacy",
                " When designing research protocols to investigate the impact of targeted prophylactic antibiotic (PAP) therapy on reducing post-transplant infections among Extended Criteria Donor (ESCR)-E colonized Solid Organ Transplant (SOT) candidates, it is essential to include several key components to ensure the study's validity, reliability, and ethical integrity. Here are the recommended elements to be included:\n\n1. **",
                " Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. However, it is essential to consider the following points:\n\n1. Individual patient assessment: The decision to administer PAP should be based on a thorough evaluation of the patient's medical history, the type of surgery, the",
                " A good practice for screening SOT (Solid Organ Transplant) recipients for CANCER (CRAB) before surgery involves a comprehensive approach that includes the following steps:\n\n\n1. **Pre-transplant Evaluation:**\n\n   - Conduct a thorough medical history and physical examination focusing on signs and symptoms of malignancy.\n\n   - Review previous imaging studies and pathology reports for any evidence of cancer.",
                " As of my last update in April 2023, there isn't a specific panel of experts or a universally recognized set of guidelines that directly suggests the design of clinical trials for investigating CRAB (Cytomegalovirus, Aspergillus, Bacterial, and other rare infections) colonization and targeted PAP (Potential Antiparasitic) therapies. However, I can",
                " Perioperative antibiotic prophylaxis (PAP) is a critical component in transplant surgery to prevent surgical site infections (SSIs). The duration of PAP in transplant surgery, other than renal transplant, is generally tailored to the type of surgery, the patient's risk factors, and the institution's protocols. However, there are some general guidelines that can be followed.\n\nFor most trans",
                " Multidrug-resistant Gram-Negative Bacteria (MDR-GNB) infections in Solid Organ Transplant (SOT) recipients are a significant clinical concern due to the high risk of morbidity and mortality associated with these infections. The risk of MDR-GNB infections in SOT recipients is influenced by several factors, including the type of organ transplanted, the immunosuppressive therapy",
                " The suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) involves a combination of clinical, microbiological, and molecular methods. Here is a step-by-step approach:\n\n1. Obtain a detailed medical history: Gather information about the patient's previous antibiotic use,",
                " As of my last update in April 2023, I don't have access to real-time databases or the ability to pull up specific studies or trial results. However, I can provide you with a general overview of what such a study might entail and the potential outcomes based on existing knowledge in the field.\n\nA randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (post-thor",
                " The association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery is a significant concern in the field of urology and infectious diseases. MDR-GNB are bacteria that have developed resistance to multiple classes of antibiotics, making them challenging to treat. These bacteria can colonize the ur",
                " Reducing surgical site infections (SSIs) requires a comprehensive approach that involves multiple strategies and the collaboration of a multidisciplinary team. Here are the key components of a comprehensive approach to reduce SSIs:\n\n1. Preoperative measures:\n   a. Patient assessment: Evaluate the patient's medical history, comorbidities, and risk factors for SSIs.\n   b. Optimization of the patient",
                " Standard Operating Procedures (SOPs) for sampling site technique and microbiological methods are essential for ensuring the consistency, reliability, and validity of microbiological analyses. Here are some general recommendations for developing SOPs in these areas:\n\n1. Define the purpose and scope: Clearly state the objectives, scope, and limitations of the SOPs. Identify the specific microbiological methods and sampling site techniques to be covered",
                " When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered:\n\n1. Patient factors: Age, comorbidities, allergies, renal and hepatic function, and previous antibiotic exposure should be taken into account.\n\n2. Infection factors: The site and severity",
                " Understanding the colonization status of a patient before solid organ transplantation (SOT) is crucial for several reasons:\n\n\n1. **Infection Risk**: The colonization of a patient with certain microorganisms can significantly increase the risk of post-transplant infections. These infections can be life-threatening and can compromise the success of the transplant.\n\n\n2. **Antibiotic Prophylaxis"
            ],
            "additional prompt / no context": [
                " The recommended targeted therapy for patients with BSI (Bacteremia and Septicemia) and severe infection due to 3GCephRE (a hypothetical antibiotic) would depend on the specific bacterial strain and its resistance profile. However, in general, targeted therapy may include the use of newer antibiotics such as ceftolozane/tazobactam, ceftazidime/avibactam",
                " The evidence on treatment of infections caused by 3GCephRE (a hypothetical antibiotic class) is organized into clinical trials, meta-analyses, and systematic reviews that evaluate the efficacy, safety, and resistance patterns of these antibiotics.",
                " The studies found that quinolones can be an effective treatment option for patients with 3GCephRE BSI, particularly in cases where the bacteria are susceptible to these antibiotics.",
                " Cephamycins and cefepime showed similar efficacy to carbapenems in treating pyelonephritis caused by 3GCephRE.",
                " The RCTs found that certain antibiotics, such as piperacillin-tazobactam, cefoperazone-sulbactam, and meropenem, were effective in treating IAI caused by 3GCephRE.",
                " Level of evidence: Level II (Randomized Controlled Trials)",
                " Level of evidence: Level C (Case series or poor-quality cohort studies)",
                " Yes, there is sufficient evidence that plazomicin has a higher efficacy and safety profile compared to colistin for the treatment of CRE infections.",
                " Yes, studies have shown that colistin-carbapenem combination therapy can reduce 28-day mortality compared to colistin monotherapy in patients with CRE infections.",
                " Cefiderocol monotherapy has shown efficacy in treating CRE infections, with studies like the CREthoric trial demonstrating its effectiveness. However, combination therapy may be preferred in certain cases to prevent resistance and improve outcomes. The choice between monotherapy and combination therapy should be based on individual patient factors, local resistance patterns, and clinical guidelines.",
                " The retrospective cohort study found that ceftolozane-tazobactam had a higher efficacy rate compared to polymyxins or aminoglycosides in treating MDR/XDR P. aeruginosa mixed infections.",
                " The treatment of severe infections caused by CRPA (Cryptosporidium-related parasitic infections) with polymyxins, aminoglycosides, or fosfomycin is not standard, as these antimicrobials are not typically used for treating parasitic infections. CRPA is usually treated with antiparasitic medications such as nitazoxanide or paromomyc",
                " The suggested treatment for patients with CRAB (Catheter-Related Bacteremia, Acute Pyelonephritis, Bacteremia, and Ventilator-Associated Pneumonia) susceptible to sulbactam and HAP/VAP (Hospital-Acquired and Ventilator-Associated Pneumonia) is a combination of antibiotics that includes a beta-lactam antibiotic such as piperacill",
                " Cefiderocol has shown high efficacy in treating CRAB infections, particularly in cases resistant to other antibiotics. It is a siderophore cephalosporin that binds to iron and is actively transported across the outer membrane of Gram-negative bacteria, including CRAB strains. Clinical trials have demonstrated its effectiveness, especially in patients with infections caused by carbapenem-res",
                " Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB infections, particularly in cases of multi-drug resistant organisms. However, the evidence is limited, and more randomized controlled trials are needed to confirm these findings.",
                " The general principles for antibiotic treatment in patients with CR-GNB (chronic relapsing neutrophilic dermatosis) infections include:\n\n1. Confirm diagnosis through biopsy and culture.\n2. Identify and treat any underlying infection or inflammatory condition.\n3. Use broad-spectrum antibiotics if an infection is suspected.\n4. Consider antifungal or antiviral",
                " The suggested screening approach for patients undergoing colorectal and liver transplant surgery includes preoperative evaluation for hepatitis B and C, HIV, and other infectious diseases. Postoperatively, patients should be monitored for signs of infection, graft rejection, and liver function. Regular screening for colorectal cancer should be considered based on individual risk factors.",
                " The recommendation for perioperative antibiotic prophylaxis in patients colonized with ESCR-E (Extended Spectrum Coagulase-negative Resistant Enterobacteriaceae) undergoing colorectal surgery is to administer a first-generation cephalosporin or a carbapenem within 60 minutes before the surgical incision.",
                " Colistin and Tigecycline",
                " Include a detailed description of the PAP targeting strategy, patient selection criteria, infection surveillance methods, and statistical analysis plan.",
                " Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis for patients colonized with CRE before surgery, but it should be based on current guidelines and local antibiotic resistance patterns.",
                " Perform a complete blood count (CBC) with differential, serum protein electrophoresis (SPEP), and urine protein electrophoresis (UPEP) to screen for CRAB (Calcium, Renal function, Anemia, and Bone lesions) before SOT recipient surgery.",
                " The panel suggests designing randomized controlled trials (RCTs) to investigate CRAB colonization and targeted PAP.",
                " The suggested duration of perioperative antibiotic prophylaxis (PAP) in transplant surgery varies depending on the type of surgery and the patient's risk factors. Generally, PAP is recommended for 24 hours for most transplant surgeries. However, for high-risk patients or surgeries with a higher risk of infection, PAP may be extended up to 7 days. It's essential to follow the specific",
                " The risk of MDR-GNB (multidrug-resistant Gram-negative bacteria) infections in solid organ transplant recipients is significant due to their immunocompromised state and the use of broad-spectrum antibiotics. Consequences include increased morbidity and mortality, longer hospital stays, and higher healthcare costs.",
                " Perform a urine culture and sensitivity test before the procedure.",
                " The outcome of such a trial would likely show that ciprofloxacin PAP is less effective in FQR carriers compared to culture-based PAP, leading to a higher rate of treatment failure in the ciprofloxacin PAP group.",
                " Urinary colonization with MDR-GNB is associated with an increased risk of postoperative infections in patients undergoing urologic surgery.",
                " A comprehensive approach to reduce SSIs includes:\n\n\n1. Preoperative measures:\n\n   - Screening and treating patients for infections.\n\n   - Optimizing patient health and nutrition.\n\n   - Administering prophylactic antibiotics appropriately.\n\n\n2. Intraoperative measures:\n\n   - Maintaining a sterile environment.\n\n   - Using proper surgical techniques and",
                " Adherence to standardized protocols for sample collection, labeling, transport, and processing is recommended. Utilize aseptic techniques to avoid contamination. Employ appropriate culture media and incubation conditions based on the suspected pathogens. Perform quality control with known positive and negative controls.",
                " Consider the patient's allergy history, local antibiogram data, and the specific CRE species involved.",
                " To prevent post-transplant infections and rejection."
            ],
            "no additional prompt / context": [
                " The recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE is a carbapenem, specifically imipenem or meropenem. This recommendation comes with a strong recommendation for use and is based on moderate certainty of evidence.",
                " The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndromes, specifically Bloodstream Infections (BSI), Urinary Tract Infections (UTI), Pneumonia, and Intra-abdominal Infections (IAI). The studies addressing these syndromes are summarized in Table 3.\n\nFor BSI, the main comparison is between the older BLBII (amox",
                " The studies evaluating quinolones as a treatment option for 3GCephRE BSI found that there is very-low-certainty evidence for the effectiveness of aminoglycosides, which are a part of the quinolone group, in treating bacteremia of urinary tract source. However, due to the small sample size and observational design of the studies, there is no direct evidence on targeted quinolone therapy for ",
                " The studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE found no significant differences between treatment groups in terms of clinical cure, relapse, and mortality. However, it's important to note that all studies were at high risk of bias and provided low-certainty evidence.",
                " The context provided does not contain specific findings from RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE. The information given focuses on the management of bloodstream infections (BSI) and urinary tract infections (UTIs) caused by 3GCephRE, with recommendations for carbapenems, piperacillin-",
                " The level of evidence for the advantage of meropenem-vaborbactam over best available treatment (BAT) for susceptible carbapenem-resistant Enterobacteriaceae (CRE) is moderate. This conclusion is based on the findings of the Tango-II trial, which included 47 patients. The trial demonstrated significantly improved cure rates at the end of treatment with meropenem-vaborbactam (65.6",
                " The level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is judged as moderate. This conclusion is based on insufficient evidence for other comparisons and other sources of infection.",
                " Based on the context provided, there is currently insufficient evidence to compare the efficacy of plazomicin to colistin for the treatment of CRE infections. The available results from the CRaCKle cohort suggest that all-cause mortality at 28 days was lower with colisitin combination therapy (which includes colistin) compared to plazomicin combination therapy. However, the study was suspended due to enrollment",
                " Based on the information provided, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. The AIDA trial showed a 35% mortality rate with colistin monotherapy (12 out of 34 patients) versus a 21% mortality rate with colistin-meropenem combination ther",
                " The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is limited and conflicting. The available studies, which are mostly observational with high risk of bias, have shown variable results. Some studies suggest that combination therapy may lead to better clinical outcomes, especially in patients with more severe disease and when the combination includes more than one in vitro active antimicrobial. However, the evidence is not strong enough",
                " The retrospective cohort study compared the use of ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with mixed infections due to MDR/XDR P. aeruginosa. The results indicated that clinical care was higher with ceftolozane-tazobactam, with an adjusted odds ratio (OR) of 2.63 (95% CI 1.",
                " The recommendation for treating severe infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA) with polymyxins, aminoglycosides, or fosfomycin is to use combination therapy with two in vitro active drugs. This recommendation is based on a conditional recommendation for use, with very low certainty of evidence. The specific combinations cannot be recommended for or against due to the lack of data.",
                " The suggested treatment for patients with CRAB (carbapenem-resistant Acinetobacter baumannii) susceptible to sulbactam and hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) is ampicillin-sulbactam (conditional recommendation, low certainty of evidence). This recommendation is based on the findings of a single-centre retrospective study in",
                " The efficacy of cefiderocol compared to other antibiotics in treating CRAB (CR-GNB bacteremia, ventilator-associated pneumonia, and healthcare-associated pneumonia) infections is not clearly established due to limited clinical experience and data. The CREDIBLE RCT (Randomized Controlled Trial) compared cefiderocol with BAT (Beta-lactam and A",
                " Observational studies have provided mixed evidence regarding the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections. Some studies have shown a significant association between the use of this combination therapy and improved survival or clinical cure when compared to polymyxin monotherapy. For instance, a study by Hussain et al. (2018) found that patients treated with a combination of polymyxin B and mer",
                " The general principles for antibiotic treatment in patients with CR-GNB (Carbapenem-Resistant Gram-Negative Bacteria) infections are as follows:\n\n1. Antibiotic stewardship: Antibiotic stewardship is a critical aspect of managing CR-GNB infections. It involves the judicious use of antibiotics to minimize the development of resistance and preserve the effectiveness of last",
                " The suggested screening approach for patients undergoing colorectal and liver transplant surgery is to implement rectal screening to identify carriers of Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) before surgery. This recommendation is based on the local epidemiology of ESCR-E colonization and infection. The screening should be considered a conditional recommendation with low certainty of evidence. It is",
                " The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery is conditionally to use targeted PAP. This recommendation is based on a conditional recommendation for use with low certainty of evidence. The studies reviewed showed that ESCR-E carriers had a higher rate of postoperative infections and SSIs compared to noncarriers, suggesting that targeted",
                " The antibiotics that should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers include novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam. These are considered reserve ant",
                " Research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates should include the following elements:\n\n1. Monitoring of antibiotic resistance: The protocols should include monitoring for the development of antibiotic resistance, particularly for carbapenem-resistant Enterobacteriaceae (CRE). This can be done through regular rectal cultures to detect CRE",
                " Based on the current evidence and recommendations, there is insufficient evidence to support or refute the use of targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. Therefore, no specific recommendation can be issued at this time.\n\nThe available studies on targeted PAP in CRE carriers before surgery have limitations, such as",
                " A good practice for screening SOT recipients for CRAB before surgery is to screen all SOT recipients according to the local epidemiology. This approach should be integrated within antibiotic and diagnostic stewardship guidance. The decision to implement screening procedures should be based on a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards. Although a prevalence threshold is not clearly",
                " The panel suggests designing clinical trials that compare the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in these trials.",
                " In transplant surgery other than renal transplant, the suggested duration of PAP is 48-72 hours. This recommendation is based on expert opinion and the specific needs of different types of transplants. For example, lung recipients with respiratory colonization or infection and intestinal or multivisceral transplant with infected mesh or fistulas may require a longer duration of PAP. However, it's important to note that this",
                " The risk of MDR-GNB infections in solid organ transplant (SOT) recipients is significant due to several factors, including prolonged hospitalization, invasive procedures, ICU admission, and broad-spectrum antibiotic treatment. These patients are exposed to MDR-GNB infections, which can lead to serious complications.\n\nThe consequences of MDR-GNB infections in SOT recipients are severe, as they",
                " The suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is rectal screening. This recommendation is based on the association between FQR-E colonization and increased rates of post-TRUSPB infectious complications. The European Association of Urology (EAU) guidelines",
                " The randomized, non-blinded, multicenter trial compared ciprofloxacin PAP (prophylactic antibiotic regimen) versus culture-based PAP (antibiotic regimen tailored to the specific bacteria identified in a patient's urine culture) in patients undergoing transrectal ultrasound-guided prostate biopsy (TRUSPB). The study included 1288",
                " The association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery is a significant concern. Studies have shown that patients with urinary colonization by MDR-GNB are at a higher risk of developing postoperative infections, particularly surgical site infections (SSIs). For instance, a small, prospective single-center",
                " The comprehensive approach required to reduce surgical site infections (SSIs) involves a multifaceted strategy that includes both antibiotic-based interventions and best surgical practices. Here are the key components of this approach:\n\n1. Targeted antibiotic prophylaxis (PAP): This involves the use of specific antibiotics to prevent SSIs in patients who are carriers of multidrug-resistant organisms (",
                " The context provided does not explicitly mention recommendations for standard operating procedures (SOPs) related to sampling site technique and microbiological methods. However, it does emphasize the importance of considering local epidemiology when implementing screening procedures for CRAB colonization before surgery. It also highlights the need for careful assessment of local prevalence of CRE colonization and infection among patients admitted or transferred to the surgical wards.\n\nTo ensure accurate and reliable",
                " When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered to ensure the effectiveness and safety of the intervention. These considerations are based on the principles of antimicrobial stewardship and the need to address the challenges posed by CRE infections. Here are the key considerations:\n\n",
                " Knowing the colonization status of a patient before solid organ transplantation (SOT) is crucial for several reasons. Firstly, it helps identify patients at risk of post-transplant infections. Certain bacteria, such as Extended Spectrum Carbapenem-Resistant Enterobacteriaceae (ESCR-E), Carbapenem-Resistant Acinetobacter Baumannii (CRAB), and Pandoraea s"
            ],
            "additional prompt / context": [
                " The recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE is a carbapenem, specifically imipenem or meropenem.",
                " The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndromes, specifically bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI). The studies are categorized based on the type of infection and the antibiotics used for treatment. The evidence is mainly derived from observational studies in hospital settings, with a focus",
                " The studies evaluating quinolones as a treatment option for 3GCephRE BSI found no significant difference between quinolones and carbapenems or piperacillin-tazobactam. However, due to the small sample size and observational design, there is very-low-certainty evidence for quinolone treatment for bacteriaemic UTI.",
                " The studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE found no significant differences between treatment groups in terms of clinical cure, relapse, and mortality. However, the certainty of the evidence was very low due to the high risk of bias and small sample sizes in the studies.",
                " The context provided does not include specific findings from RCTs evaluating antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE. The information given focuses on bloodstream infections (BSI) and urinary tract infections (UTI), with recommendations for carbapenems and other antibiotics based on the severity of the infection and antibiotic",
                " The level of evidence for the advantage of meropenem-vaborbactam over best available treatment (BAT) for susceptible CRE is moderate. This conclusion is based on a small study (Tango-II) that showed significantly improved cure rates at the end of treatment with meropenem-vaborbactam compared to BAT monotherapy or combinations of other antibiotics.",
                " The level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is judged as moderate. This conclusion is based on insufficient evidence for other comparisons and other sources of infection.",
                " No, there is currently insufficient evidence comparing the efficacy of plazomicin to colistin for the treatment of CRE infections.",
                " No, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections based on the subgroup analysis of the AIDA and OVERCOME trials.",
                " The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is conflicting and of very low certainty due to the observational nature of most studies and the variability in treatment schemes. Mortality rates were higher in the cefiderocol arm in one study, but the difference was not statistically significant and did not separate CRE from other CR-GNB. A subgroup analysis suggested non-inferiority of",
                " The retrospective cohort study found that clinical care was higher with ceftolozane-tazobactam compared to polymyxins or aminoglycosides (adjusted odds ratio [OR] 2.63, 95% confidence interval [CI] 1.31-5.30). Additionally, nephrotoxicity was lower with ceftolozane-tazobactam (adjust",
                " The recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use two in vitro active drugs in combination therapy. This recommendation is based on very low certainty of evidence and is considered a conditional recommendation for use.",
                " For patients with CRAB susceptible to sulbactam and HAP/VAP, the suggested treatment is ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
                " Cefiderocol has shown non-inferiority to other antibiotics in treating CRAB infections, particularly in patients with MBL-producing CRE. However, the evidence is of low certainty, and there is no clear advantage in terms of clinical or microbiological eradication. In the CREDIBLE trial, cefiderocol was associated with higher mortality rates compared to BAT in patients with CRAB in",
                " Observational studies have shown mixed results regarding the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections. Some studies have reported a significant association between the use of this combination therapy and improved survival or clinical cure when compared to polymyxin monotherapy. However, other studies did not find a significant difference in outcomes between the combination therapy and monotherapy. It's important to note that many of these",
                " The general principles for antibiotic treatment in patients with CR-GNB infections include:\n\n1. Antibiotic stewardship: Considering the use of older, in vitro active antibiotics on an individual basis and according to the source of infection.\n\n2. Empirical treatment: Targeting specific pathogens among patients considered at high risk for CR-GNB infections before pathogen identification.\n\n3. Local",
                " The suggested screening approach for patients undergoing colorectal and liver transplant surgery is to implement rectal screening to identify ESCR-E carriers before surgery. This recommendation is based on the local epidemiology of ESCR-E colonization and infection. The screening should be considered for all SOT recipients according to the local epidemiology.",
                " Conditional recommendation for targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery.",
                " The antibiotics that should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers include novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam. These are considered reserve ant",
                " Research protocols should include monitoring of antibiotic resistance, specifically CRE colonization through rectal cultures, and reporting antimicrobial susceptibility according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
                " No, a recommendation cannot be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery at the time of writing due to insufficient evidence.",
                " A good practice for screening SOT recipients for CRAB before surgery is to screen according to the local epidemiology. This means that the decision to screen should be based on the prevalence of CRAB colonization in the local patient population. If the prevalence is equal to or greater than 10%, it may be considered for implementation evaluation.",
                " The panel suggests designing clinical trials to compare the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in these trials.",
                " The suggested duration of PAP in transplant surgery other than renal transplant is 48-72 hours. This recommendation is based on expert opinion and the specific needs of different types of transplants.",
                " MDR-GNB infections in SOT recipients are associated with a significant risk. The rates of ESCR-E infections can range from 6% to 13%, while CRAB and MDR PA infections can occur in up to 63% and 52% of cases, respectively. These infections are linked to higher mortality rates compared to infections caused by susceptible bacteria. Additionally, post-",
                " The suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is rectal screening. This recommendation is based on the moderate certainty of evidence and is considered a conditional recommendation. The screening aims to identify patients who are colonized with FQR-E to tailor the prophylactic ant",
                " The trial showed a risk reduction of -1.8% in the 7-day post-TRUSPB infection rate with ciprofloxacin PAP compared to culture-based PAP. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
                " The association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery is significant. Studies have shown that patients with urinary colonization by MDR-GNB are at a higher risk of developing postoperative infections, particularly surgical site infections (SSIs). For instance, a small, prospective single-center study found",
                " The comprehensive approach to reduce surgical site infections (SSIs) involves a combination of antibiotic-based interventions and best surgical practices. This includes targeted antibiotic prophylaxis (PAP), stewardship initiatives to monitor and contain the consequences of new prescription patterns, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach to target",
                " Standard operating procedures (SOPs) for sampling site technique and microbiological methods should be based on local epidemiology and integrated within antibiotic and diagnostic stewardship guidance. The choice between targeted and universal screening should consider the local work organization. It is essential to have knowledge of the colonization status before surgery to implement infection control procedures effectively.",
                " When choosing targeted PAP for CRE infections, considerations should include:\n\n1. Limited options: There are few effective treatment options for CRE infections, so the choice of targeted PAP should focus on the available antibiotics that are effective against CRE.\n2. Avoid novel compounds: To prevent the development of further antibiotic resistance, it is recommended to avoid using novel compounds that may be required for the treatment of",
                " Knowing the colonization status of a patient before SOT is crucial for several reasons. Firstly, it helps identify patients at risk of post-transplant infections, particularly those caused by multidrug-resistant organisms (MDROs). This knowledge allows for the implementation of targeted preventive measures, such as prophylactic antibiotics or enhanced infection control procedures, to reduce the risk of infections. Secondly, it aids"
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.1088473882369812,
                    "2_gram": 0.178305007471309,
                    "3_gram": 0.1240374471841939,
                    "4_gram": 0.08514447609357859
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.23176734085775652,
                        "recall": 0.4107646675810394,
                        "fmeasure": 0.2835333998617834
                    },
                    "rouge_L": {
                        "precision": 0.16555504290289813,
                        "recall": 0.30785210766774507,
                        "fmeasure": 0.20636450676928808
                    }
                },
                "METEOR": 0.22999258626625801,
                "BERTScore": {
                    "Precision": 0.013,
                    "Recall": 0.151,
                    "F1_measure": 0.081
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.236768642609543,
                    "2_gram": 0.28346985803017194,
                    "3_gram": 0.1910561012460386,
                    "4_gram": 0.13375662444525888
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.34553796791583463,
                        "recall": 0.3001404587973551,
                        "fmeasure": 0.279628118729639
                    },
                    "rouge_L": {
                        "precision": 0.2701358805412013,
                        "recall": 0.22722074858300123,
                        "fmeasure": 0.21307049980262727
                    }
                },
                "METEOR": 0.18648413272011577,
                "BERTScore": {
                    "Precision": 0.159,
                    "Recall": 0.141,
                    "F1_measure": 0.149
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.11787999182745716,
                    "2_gram": 0.2119352273090081,
                    "3_gram": 0.1874738819778413,
                    "4_gram": 0.14898195869210865
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3713773741704289,
                        "recall": 0.6383166494126915,
                        "fmeasure": 0.4434374975873808
                    },
                    "rouge_L": {
                        "precision": 0.26845599064145154,
                        "recall": 0.4846921005827338,
                        "fmeasure": 0.32698550856027214
                    }
                },
                "METEOR": 0.4038281416079521,
                "BERTScore": {
                    "Precision": 0.21,
                    "Recall": 0.417,
                    "F1_measure": 0.311
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.15362336704678642,
                    "2_gram": 0.27576320988225583,
                    "3_gram": 0.2657686488323553,
                    "4_gram": 0.21924540479987525
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.5138176122357008,
                        "recall": 0.6943206082453568,
                        "fmeasure": 0.5598547934117126
                    },
                    "rouge_L": {
                        "precision": 0.40287439633986777,
                        "recall": 0.5412123302944002,
                        "fmeasure": 0.436804774936004
                    }
                },
                "METEOR": 0.4942951199072769,
                "BERTScore": {
                    "Precision": 0.412,
                    "Recall": 0.52,
                    "F1_measure": 0.465
                }
            }
        }
    },
    {
        "parameters": {
            "embedding model": "NeuML/pubmedbert-base-embeddings",
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 256,
            "overlap": 25,
            "top_k": 5,
            "max new tokens": 100,
            "re-ranking": 0,
            "top_n": 0
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the studies evaluating quinolones as a treatment option for 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "The studies found limited evidence on targeted quinolone therapy for 3GCephRE BSI, with one study reporting an association between quinolone treatment and lower mortality, but the analysis was limited by small sample sizes and potential biases, and therefore, there is no direct evidence to support the use of quinolones for targeted therapy.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-resistant Enterobacterales, or 3GCephrasporin-resistant K. pneumoniae, 3GCephraspor",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized",
                "Several studies have evaluated the use of quinolones as a treatment option for 3rd generation cephalosporin-resistant bloodstream infections (3GCephRE BSIs). Here are some key findings from these studies:\n\n1. Quinolones are effective against 3GCephRE BSIs caused by common pathogens such as Enterococcus faecium, Pseudomonas aeruginosa, and Klebsiella pneum",
                "Several studies have compared the effectiveness and safety of cephamycins (cefotetan and ceftriaxone), cefepime, and carbapenems (imipenem and meropenem) for the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase producing Enterobacteriaceae (3GCephre).\n\nA systematic review and meta-analysis of 12 randomized controlled trials (",
                "Several randomized controlled trials (RCTs) have evaluated the effectiveness of various antibiotics for the treatment of intra-abdominal infections (IAIs) caused by third-generation cephalosporin-resistant Enterobacterales (3GCRE). Here are some key findings from these studies:\n\n1. Carbapenems: Carbapenems, such as imipenem, meropenem, and ertapen",
                "Meropenem-vaborbactam (MVB) is a carbapenem-beta-lactamase inhibitor combination antibiotic that has shown activity against certain carbapenem-resistant Enterobacterales (CRE), including those producing NDM-1 and OXA-48-type carbapenemases. The advantage of MVB over best available treatment for susceptible CRE is supported by several studies with varying levels of evidence",
                "The comparative effectiveness and safety of aminoglycosides versus tigecycline for the treatment of complicated urinary tract infections (cUTI), including uncomplicated cUTI, have been studied in several randomized controlled trials (RCTs) and meta-analyses.\n\nA systematic review and meta-analysis of 11 RCTs involving 3,512 patients published in the Cochrane Database of Systematic Reviews in",
                "Plazomicin and colistin are both antibiotics used in the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), but the evidence comparing the two drugs in terms of efficacy, safety, and optimal use is still evolving.\n\nPlazomicin is a new generation aminoglycoside with improved activity against CRE compared to older aminoglycosides. A phase 3 clinical trial,",
                "Several studies have investigated the difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with infections caused by Carbapenem-resistant Enterobacterales (CRE), including those caused by Klebsiella pneumoniae and other Enterobacterales. The results of these studies have been inconsistent.\n\nSome studies have reported no significant difference in 28-day mortality",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE), including Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is still emerging, and the optimal approach is not yet fully established.",
                "I apologize for any confusion, but I cannot provide you with the specific results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections as there seems to be no published study with that exact title and inclusion criteria.\n\nHowever, there have been several studies investigating the effectiveness and safety of ceft",
                "CRPA (Carbapenem-resistant Pseudomonas aeruginosa) infections can be challenging to treat due to the resistance of the bacteria to many antibiotics. Polymyxins, aminoglycosides, and fosfomycin are commonly used antibiotics for the treatment of CRPA infections.\n\nPolymyxins, such as polymyxin B and E, are considered the first-line antibiot",
                "For patients with CRAB (Clostridioides difficile-related complications, including severe colitis, fulminant colitis, toxic megacolon, and sepsis) who are susceptible to sulbactam and have healthcare-associated pneumonia (HAP) or ventilator-associated pneumonia (VAP), the suggested treatment may depend on the severity of the infection and the patient's overall condition.\n\nFirst",
                "Cefiderocol is a siderophore cephalosporin antibiotic that is approved for the treatment of complicated intra-abdominal infections, including those caused by susceptible Gram-negative bacteria. CRAB (community-acquired or nosocomial acquisition, recurrent or persistent, intra-abdominal infections) is a specific type of intra-abdominal infection.\n\nSeveral studies have evaluated the effic",
                "Polymyxin-carbapenem combination therapy has been studied as a potential treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections based on the synergistic effect of both antibiotics. However, the evidence from observational studies on the effectiveness of this combination therapy is limited and often inconsistent.\n\nOne study published in the Journal of Antimicrobial Chemotherapy in 201",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections are a significant challenge in clinical microbiology due to the increasing resistance of these bacteria to commonly used antibiotics. Here are some general principles for antibiotic treatment in patients with CR-GNB infections:\n\n1. Identify the specific CR-GNB causing the infection through microbiological culture and susceptibility testing. This information is crucial for selecting the most effective antibi",
                "Patients undergoing colorectal and liver transplant surgery require careful preoperative evaluation due to the complex nature of these procedures and the potential for complications. Here are some suggested screening approaches for these patients:\n\n1. Colorectal Transplant Surgery:\n- Preoperative assessment should include a thorough history and physical examination, with a focus on the gastrointestinal system.\n- Laboratory tests: Complete blood count, coagulation studies, electro",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Resistive-Escherichia coli (ESCR-E) undergoing colorectal surgery is not well-defined due to a lack of clear consensus in the literature. However, some guidelines suggest considering PAP based on the risk of surgical site infection (SSI) and the specific characteristics of the patient and the organ",
                "Extensively drug-resistant Enterococci (ESCR-E) and extensively drug-resistant Pseudomonas aeruginosa (ESCR-PA) are bacteria that have developed resistance to most or all available antibiotics. The treatment of infections caused by these bacteria is a challenge, and the use of last-resort antibiotics should be reserved for specific cases.\n\nThe European Society of Clinical Microbiology and Infectious Dise",
                "Research protocols investigating the impact of targeted PAP (pneumococcal and other encapsulated bacteria prevention using antibiotics) in reducing post-transplant infections among Extended-Spectrum Cephalosporin Resistant-Enterococcus (ESCR-E) colonized Solid Organ Transplant (SOT) candidates should include the following elements:\n\n1. Study Design: Clearly define the study design, including the type of study (",
                "Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. The goal of PAP is to reduce the risk of surgical site infections (SSIs). In patients colonized with CRE, the risk of developing SSIs is increased due to the potential for carrying antibiotic-resistant bacteria. Therefore, targeted",
                "Screening SOT (solid organ transplant) recipients for CRAB (chronic rejection, acute rejection, banff lesions) before surgery involves a comprehensive evaluation to assess the current status of the transplanted organ and the overall health of the recipient. Here are some good practices for screening SOT recipients for CRAB before surgery:\n\n1. Review of medical history: A thorough review of the recipient's medical history, including details of the transplant procedure",
                "To investigate CRAB (Candida auris-related bloodstream infections) colonization and targeted PAP (positive blood culture identification and antimicrobial stewardship), the following types of clinical trials could be suggested:\n\n1. Prospective observational studies: These studies can be used to assess the prevalence and incidence of CRAB colonization in different patient populations and settings. They can also evaluate the effectiveness of targeted PAP in identifying CRAB in",
                "In transplant surgery other than renal transplants, the suggested duration of post-anesthesia care unit (PACU) or post-operative recovery varies depending on the specific type of transplant and the individual patient's condition. Here are some general guidelines for different types of transplants:\n\n1. Liver transplant: Patients typically stay in the PACU for 1-2 days after the surgery. However, some patients may require a longer",
                "MDR-GNB (Multidrug-resistant Gram-negative bacteria) infections are a significant concern in solid organ transplant (SOT) recipients due to their increased susceptibility to infections and the potential for antibiotic resistance. The risk of MDR-GNB infections in SOT recipients varies depending on several factors, including the type of transplant, the underlying condition of the patient, and the exposure to healthcare environments.\n\nAccording to a",
                "The identification of fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is important to reduce the risk of post-biopsy infections and potential development of antibiotic-resistant bacteria. Here are some suggested approaches to identify FQR-E carriers:\n\n1. Pre-biopsy urine culture: Ob",
                "A randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (Prostate Antigen Percentage using ciprofloxacin as a urinary selective inhibitor of bacterial growth) and culture-based PSA (Prostate Specific Antigen) in patients undergoing Transrectal Ultrasound-Guided Prostate Biopsy (TRUSPB) would provide data on the diagnostic accuracy and utility",
                "Urinary colonization with MDR-GNB has been identified as a risk factor for postoperative infections in patients undergoing urologic surgery. The presence of MDR-GNB in the urine before surgery increases the likelihood of developing postoperative infections, particularly urinary tract infections (UTIs).\n\nStudies have shown that the incidence of urinary colonization with MDR-GNB is higher in patients undergoing urologic surgery compared to",
                "Reducing surgical site infections (SSIs) requires a comprehensive approach that addresses various factors before, during, and after surgery. Here are some key elements of a comprehensive approach to reducing SSIs:\n\n1. Preoperative preparation:\n   a. Proper patient selection and optimization\n   b. Timely and appropriate antibiotic prophylaxis\n   c. Controlling risk factors such as diabetes, obesity, and malnutrition\n   d.",
                "Standard Operating Procedures (SOPs) for sampling site techniques and microbiological methods are essential to ensure consistency, accuracy, and reliability of data obtained from environmental or laboratory investigations. Here are some recommended practices for developing SOPs in these areas:\n\n1. Sampling Site Techniques:\n\na. Define the sampling objectives, location, and frequency.\nb. Establish a chain of custody for samples to maintain their integrity from the time of collection to",
                "When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered to optimize the effectiveness of the antibiotic prophylaxis and minimize the risk of selecting for antibiotic resistance or causing adverse effects. Some of these factors include:\n\n1. Timing of administration: PAP should be administered within one hour before the surg",
                "Colonization status refers to the presence of potentially harmful bacteria in the body, particularly in the gastrointestinal tract, that do not cause infection in a healthy individual but can cause infections after a solid organ transplantation (SOT). These infections, known as translocation infections, can lead to significant morbidity and mortality in transplant recipients.\n\nThe importance of knowing the colonization status of a patient before SOT lies in the fact that certain"
            ],
            "additional prompt / no context": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum \u03b2-lactamase producing Klebsiella pneumoniae (3GCephrasporin-resistant, or 3GCephrE), the recommended targeted therapy is usually a carbapenem antibiotic, such as meropenem or imipenem. Other options may include polymyxins or aminocoumarins,",
                "The evidence on the treatment of infections caused by third-generation cephalosporin-resistant bacteria (3GCRE) is organized through numerous studies, meta-analyses, and guidelines. These sources provide evidence on the effectiveness and safety of various antibiotics, including carbapenems, aminoglycosides, and polymyxins, among others. The Infectious Diseases Society of America (IDSA) and European Society of Clin",
                "Quinolones have shown effectiveness in treating 3GCephalosporin-resistant bloodstream infections (BSIs). However, resistance to quinolones is increasing, so their use should be reserved for infections caused by susceptible bacteria. Adverse effects, including peripheral neuropathy and tendinitis, should be monitored closely.",
                "The studies suggest that cephamycins and cefepime are comparable to carbapenems in terms of clinical cure rates for pyelonephritis caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). However, higher resistance rates to cephamycins and cefepime may require larger doses or alternative agents.",
                "The RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3rd-generation cephalosporin-resistant (3GCephR) bacteria have shown that:\n\n1. Carbapenems (imipenem, meropenem) are effective in treating 3GCephR-IAI.\n2. Aminoglycosides (gentamicin,",
                "The level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible Carbapenem-resistant Enterobacterales (CRE) is high, based on numerous randomized controlled trials and meta-analyses demonstrating superior clinical response and microbiological eradication rates.",
                "The evidence for the advantage of aminoglycosides over tigecycline for complicated urinary tract infections (cUTI) is inconclusive. Some studies suggest that aminoglycosides may have similar efficacy to tigecycline, while others suggest that tigecycline may have a slightly better safety profile. Ultimately, the choice between these antibiotics depends on individual patient factors and clinician preference.",
                "Plazomicin, a new antibiotic, has shown promise in clinical trials for the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), including those that are resistant to colistin. However, more data from larger, randomized controlled trials are needed to definitively establish the superiority of plazomicin over colistin in terms of clinical outcomes, safety, and resistance development. Therefore, the evidence is not yet sufficient",
                "Yes, there are studies suggesting that colistin-carbapenem combination therapy may have a lower 28-day mortality rate compared to colistin monotherapy in patients with Carbapenem-resistant Enterobacteriaceae (CRE) infections. However, the evidence is not definitive, and more research is needed to confirm these findings. It's important to note that individual patient outcomes can vary significantly based on factors such as underlying health conditions and",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE). The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections comes from several clinical studies.\n\nA randomized controlled trial (RCT) by Bekas et al. (2019) showed that monotherapy with cefiderocol led to similar",
                "The retrospective cohort study found that ceftolozane-tazobactam was associated with a higher clinical cure rate (83.3%) compared to polymyxins or aminoglycosides (63.6%) in patients with MDR/XDR P. aeruginosa mixed infections. However, it's important to note that retrospective studies have limitations, and more well-designed studies are needed to confirm these",
                "For severe infections caused by CRPA (Carbapenem-resistant Pseudomonas aeruginosa), the recommended antibiotic regimens include:\n\n1. Polymyxins (e.g., polymyxin B or E) in combination with an aminoglycoside (e.g., gentamicin or tobramycin).\n2. Monotherapy with a newer polymyxin (e.g",
                "For patients with CRAB (Carbapenem-resistant Acinetobacter baumannii) and susceptible to sulbactam but resistant to other antibiotics in the setting of HAP (Healthcare-associated pneumonia) or VAP (Ventilator-associated pneumonia), the suggested treatment options may include:\n\n1. Polymyxins (e.g., colistin or polymyxin",
                "Cefiderocol is an antibiotic with activity against gram-negative bacteria, including those commonly responsible for CRAB (community-acquired or healthcare-associated carbapenem-resistant acinetobacter baumannii) infections. Several studies have shown that cefiderocol is effective in treating CRAB infections, with success rates similar to or superior to other antibiotics such as colistin and tigecycline. However, it",
                "Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB (Carbapenem-resistant Acinetobacter baumannii) infections. However, high-quality randomized controlled trials are needed to provide stronger evidence of its efficacy and safety. The combination therapy may improve outcomes by synergistic effects of both antibiotics against carbapenem-resistant A. baumannii.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections require specific antibiotic treatment due to their resistance to commonly used antibiotics. Here are some general principles for antibiotic treatment:\n\n1. Identify the specific CR-GNB causing the infection through laboratory testing.\n2. Choose an antibiotic that is active against the identified CR-GNB.\n3. Consider the site of infection, severity, and patient",
                "For patients undergoing colorectal transplant surgery, preoperative screening typically includes colonoscopy to assess for colon cancer or precancerous lesions. For liver transplant patients, screening may include hepatitis serology, imaging studies like ultrasound or CT scan, and tumor markers like AFP. The specific screening approach may vary depending on individual patient risk factors and transplant type. Always consult with a healthcare professional for personalized medical advice.",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Cephalosporin-Resistant Enterococci (ESCR-E) undergoing colorectal surgery is controversial. Some guidelines suggest considering alternative antibiotics for PAP, while others recommend using a different class of antibiotics altogether, such as aminoglycosides or glycopeptides. Ultimately",
                "The antibiotics that should be reserved for the treatment of extensively resistant bacteria (such as extensively drug-resistant Mycobacterium tuberculosis or carbapenem-resistant Enterobacteriaceae) include:\n\n1. Polymyxins (e.g., colistin)\n2. Aminoglycosides (e.g., amikacin, gentamicin)\n3. Tigecycline",
                "Recommended components for research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates include:\n\n1. Study design: Randomized controlled trials (RCTs) or observational studies.\n2. Study population: ESCR-E colonized SOT candidates.\n3. Intervention: Targeted PAP (pre-transplant antimicrobial prophylaxis)",
                "Yes, a recommendation can be issued for targeted PAP for patients colonized with CRE before surgery to reduce the risk of surgical site infections caused by these bacteria. However, the specific antibiotic choice should be based on local resistance patterns and potential for cross-resistance. Consult local guidelines and infectious disease specialists for the most appropriate antibiotic selection.",
                "A good practice for screening Solid Organ Transplant (SOT) recipients for CRAB (Chronic Renal Allograft Abolition) before surgery is to assess their renal function with regular serum creatinine levels and estimated glomerular filtration rate (eGFR). Additionally, monitoring for proteinuria, hematuria, and signs of allograft dysfunction is essential. If there are concerns, a renal biopsy may be necessary",
                "To investigate CRAB (Clostridioides difficile-related antibiotic-associated bacterial) colonization and targeted PAP (phage-based antibiotic prophylaxis), the panel would suggest designing randomized controlled trials (RCTs) with a placebo or active comparator arm. These trials should include adequate sample size, proper power analysis, and appropriate endpoints to assess the efficacy and safety of targeted PAP in preventing CRAB colon",
                "In transplant surgery other than renal transplant, the suggested duration of post-operative positive airway pressure (PAP) varies depending on the specific type of transplant and individual patient's condition. Generally, it ranges from a few days to several weeks. For example, in liver transplant, PAP may be used for a few days to help prevent respiratory complications. In heart-lung transplant, PAP may be required for several weeks to help the",
                "The risk of Multidrug-resistant Gram-negative bacterial (MDR-GNB) infections in solid organ transplant (SOT) recipients is relatively high due to the use of immunosuppressive medications. These infections can lead to serious complications such as sepsis, organ failure, and increased mortality. Common MDR-GNB pathogens include P. aeruginosa, Acinetobacter baumannii, and Kle",
                "The suggested approach to identify FQR-E carriers before TRUSPB includes:\n\n1. Obtaining a urine culture before the procedure.\n2. Sensitivity testing for fluoroquinolones in the urine culture result.\n3. Considering alternative antibiotics for prophylaxis if FQR-E is identified.\n\nIt's important to note that the decision to test for FQR-E should be based on local",
                "The specific outcome of the trial you're referring to is not readily available in a clear and short answer format, as I would need to access the study's results to provide an accurate response. However, in general, non-blinded trials may be subject to bias, and comparing ciprofloxacin PAP (prostate antimicrobial prostatease) to culture-based PAP (transrectal ultrasound-guided prostate bi",
                "Urinary colonization with MDR-GNB is a significant risk factor for postoperative infections in patients undergoing urologic surgery. These bacteria can cause infections during or after the procedure, leading to increased morbidity and mortality. Preoperative urine screening and appropriate antibiotic prophylaxis can help reduce the risk of these infections.",
                "A comprehensive approach to reducing surgical site infections (SSIs) includes:\n\n1. Preoperative preparation: Optimizing the patient's health, proper wound preparation, and prophylactic antibiotics.\n2. Intraoperative measures: Sterile environment, proper surgical technique, and use of sterile instruments.\n3. Postoperative care: Wound care, early ambulation, and appropriate use of drains and dressings.\n4.",
                "For standard operating procedures (SOPs) related to sampling site technique, it's important to follow these steps:\n\n1. Properly clean and prepare the sampling site.\n2. Use sterile equipment for sampling.\n3. Collect sufficient sample size.\n4. Transport samples to the lab in appropriate containers and at proper temperature.\n\nFor microbiological methods, SOPs should include:\n\n1. Properly handling and transporting samples.",
                "When choosing targeted PAP for CRE infections, consider the following factors:\n\n1. Type and location of the surgery: The risk of surgical site infection (SSI) varies depending on the type and location of the surgery.\n2. Patient risk factors: Factors such as age, comorbidities, and underlying conditions increase the risk of SSIs.\n3. Type and susceptibility of the CRE isolate: The specific type and susceptibility of",
                "Colonization of a patient with bacteria or other pathogens that can cause infections is important to consider before solid organ transplantation (SOT) because these infections can lead to graft failure, increased morbidity, and mortality. Immunosuppressive drugs used after transplantation can weaken the patient's immune system, making them more susceptible to infections. Knowing the colonization status allows healthcare providers to take appropriate measures to prevent or treat"
            ],
            "no additional prompt / context": [
                "The recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE is a carbapenem (imipenem or meropenem) (strong recommendation for use, moderate certainty of evidence).",
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including Bloodstream infections (BSI), Urinary Tract Infections (UTI), pneumonia, and Intra-abdominal Infections (IAI). For each syndrome, recommendations are provided based on the available evidence.\n\n        For BSI, the MERINO trial compared piperacillin-tazobactam with meropenem among patients",
                "The studies evaluating quinolones as a treatment option for 3GCephRE BSI reported favorable effects in studies assessing Gram-negative bacteriaemia in general, but there is no direct evidence on targeted quinolone therapy for 3GcephRE BSI due to the small number of patients and the fact that quinolones were given as stepdown therapy to stable patients. Therefore, more research is needed to determine the efficacy and safety of qu",
                "Based on the context provided, none of the retrospective cohort studies found statistically significant differences between cephamycins and cefepime groups and carbapenem groups for the treatment of pyelonephritis caused by 3GCephRE. However, all studies were at high risk of bias and had very small sample sizes, providing low-certainty evidence for cephamycins and cefepime for the treatment of pyeloneph",
                "The context above mentions several retrospective cohort studies comparing cephamycins and cefepime with carbapenems for the treatment of pyelonephritis caused by 3GCephRE, but none of these studies found statistically significant differences between groups with very small sample sizes and high risk of bias. There is low-certainty evidence for cepamymcins and cefepime for the treatment of pyelonephritis",
                "Based on the Tango-II RCT mentioned in the context, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE. This study showed significantly improved cure rates and non-significantly lower 28-day mortality in the meropenem-vaborbactam group compared to other treatment options. However, it's important to note that the evidence is still subject to some",
                "The level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is moderate. The evidence includes studies that have shown an advantage of aminoglycosides over tigecycline for cUTI caused by CRE, although some of these studies were at high risk of bias. There is also insufficient evidence for other comparisons and other sources of infection.",
                "Based on the context provided, there is currently insufficient evidence on the comparative efficacy and safety of plazomicin versus colistin for the treatment of CRE infections. The available data comes from a single study that showed a lower all-cause mortality at 28 days with plazomicin combination therapy compared to colistin combination therapy in patients with CRE and BSI. However, the study was suspended after 2 years due to enrolment",
                "Based on the information provided in the context, there is no significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections, according to the subgroup analysis of the AIDA and OVERCOME trials. However, it is important to note that the evidence is moderate-certainty and the heterogeneity of treatments included in smaller studies makes it difficult to draw firm conclusions",
                "Based on the available evidence, the clinical and microbiological efficacies of cefiderocol monotherapy and combination therapy in the treatment of CRE infections are similar. However, there is low-certainty evidence for the non-inferiority of cefiderocol compared with other antibiotics for MBL-producing CRE. There is no clinical experience evaluating the use of aztreonam monotherapy in the treatment of CRE infections,",
                "The retrospective cohort study compared the clinical care and nephrotoxicity of ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections. The study found that clinical care was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephro",
                "The recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combinations can be recommended or opposed.",
                "Based on the available evidence, for patients with CRAB infections that are susceptible to sulbactam and HAP/VAP, ampicillin-sublactam is suggested as a treatment option (conditional recommendation, low certainty of evidence).",
                "Based on the available evidence, we conclude on low-certainty evidence for the non-inferiority of cefiderocol compared to other antibiotics for MBL-producing CRE infections. However, for CRAB infections specifically, the evidence against the use of cefiderocol is stronger, and we conditionally recommend against its use (low certainty of evidence). There is no clinical experience evaluating the use of aztreonam monotherapy in",
                "Based on the context provided, there have been several observational studies assessing the combination of polymyxins and carbapenems specifically for CRAB infections. Some of these studies showed a significant association between the use of the combination and survival or clinical cure [198, 235, 247]. However, it's important to note that many of these studies included patients treated with a polymyxin-carbapenem combination in",
                "1. For patients with severe CR-GNB infections that are susceptible in vitro only to polymyxin, aminoglycosides, tigecycline, or fostomycin, or in the absence of new BLBLI, treatment with more than one drug active in vitro is recommended (conditional recommendation, moderate certainty of evidence).\n        2. Carbapenem-based combination therapy for CR-GNB infections is not",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epidemiology (",
                "Based on the context provided, the recommendation is for conditionally recommending targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery (conditional recommendation for use, low certainty of evidence). It might also be a good practice to consider targeted PAP for all SOT recipients who are colonized with ESCR-E before surgery (ungraded good practice statement).",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers due to",
                "1. Postsurgical monitoring of antibiotic resistance: This includes CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n        2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n        3. Considering the local burden of ESCR-E and patient-related risk factors for carrier status, such as",
                "Based on the current evidence, there is no recommendation for targeted PAP for CRE carriers before surgery. However, the knowledge of CRE colonization in high-risk patients, such as those undergoing transplant surgery, is relevant for infection control purposes and for the adaptation of postsurgical empirical treatment. The panel suggests designing clinical trials to assess the impact of CRE rectal screening in high-risk surgeries and to evaluate the effectiveness, applicability, and safety",
                "It might be a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology (ungraded good practice statement). Any change in procedures should consider evidence-based screening protocols and be integrated within antibiotic and diagnostic stewardship guidance. The knowledge of the colonization status of the patient before SOT is essential for early implementation of infection control procedures.",
                "The panel suggests designing clinical trials to assess the impact of CRAB rectal screening in high-risk surgeries, specifically investigating the incidence risk of CRAB infections in carriers versus non-carriers and the efficacy of targeted versus routine PAP in CRAB carriers.",
                "Based on current recommendations from the Infectious Diseases Society of America, American Society of Health-System Pharmacists, Surgical Infection Society, and Society for Healthcare Epidemiology of America, as well as other international societies, the suggested duration of PAP in transplant surgery other than renal transplant is 24-48 hours [3,54,49,50,51,52,53,54].",
                "The risk of MDR-GNB infections in solid organ transplant (SOT) recipients varies depending on the type of organ transplanted and the geographic area. According to available data, SSIs are a common issue in SOT recipients, with highest rates observed for intestinal, liver, and pancreas transplantation. Intra-abdominal infections, particularly in the early post-transplant period, are a significant concern for liver-",
                "Based on the evidence reviewed, it is recommended to perform rectal screening to identify FQR-E carriers before TRUSPB. This is a conditional recommendation with moderate certainty of evidence.",
                "The recently published randomized, non-blinded, multicenter trial compared ciprofloxacin PAP versus culture-based PAP in 1288 patients undergoing TRUSPB, including 15.8% FQR carriers. The study showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TR",
                "Based on the available evidence, there is a correlation between urinary colonization with MDR-GNB and an increased risk of postoperative infections in patients undergoing urologic surgery. However, the literature is limited, and further research is required to establish the impact of targeted preoperative antibiotic prophylaxis (PAP) based on preoperative cultures, including urinary cultures, on postoperative infections. The optimal targeted PAP for different MDR",
                "A comprehensive approach to reducing SSIs requires a focus on both antibiotic-based interventions and best surgical practices. This includes minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, and managing patient comorbidities. Additionally, heightening stewardship initiatives are necessary to monitor and contain the consequences of new prescription patterns, enhance surveillance protocols, improve local adherence to guidelines, and promote a multidisciplinary approach",
                "Based on the context provided, there is no specific recommendation mentioned for standard operating procedures related to sampling site technique and microbiological methods for MDR-GNB colonized patients before urologic surgery. However, it is recommended to follow evidence-based screening protocols and integrate antibiotic and diagnostic stewardship guidance when considering any changes in procedures. The choice of targeted versus universal screening should be based on the local work organization. The knowledge of the colonization status of the patient before surgery",
                "1. CRE colonization in high-risk patients, such as those undergoing transplant surgery, is relevant not only for infection control purposes but also for the adaptation of postsurgical empirical treatment.\n2. The choice of targeted PAP should consider the limited number of options available for the treatment of CRE infections, avoiding novel compounds that may be required for the treatment of postsurgical infections.\n3. Resistance monitoring should be performed through detection of M",
                "Knowing the colonization status of a patient before solid organ transplantation (SOT) is essential for early implementation of infection control procedures. This information can help reduce the risk of intra-hospital and community spreading of multidrug-resistant bacteria (MDR-GNB), such as carbapenem-resistant Enterobacterales (CRE), which are known to cause infections in SOT recipients. These infections can lead to higher mortality compared with"
            ],
            "additional prompt / context": [
                "The recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE is a carbapenem (imipenem or meropenem) (strong recommendation for use, moderate certainty of evidence).",
                "1.1 The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome: BSI, UTI, pneumonia, and IAI. Recommendations for each syndrome are provided based on the available evidence from clinical trials and observational studies.\n        \n        1.2 For BSI, the MERINO trial compared piperacillin-tazobactam with meropenem for patients with 3GCephRE",
                "The studies evaluating quinolones as a treatment option for 3GCephRE BSI reported favorable effects in studies assessing Gram-negative bacteriaemia in general, but there is no direct evidence on targeted quinolone therapy for 3GcephRE BSI due to the small sample sizes and the fact that quinolones were given as stepdown therapy to stable patients.",
                "Based on the context provided, none of the retrospective cohort studies found statistically significant differences between cephamycins and cefepime groups and carbapenem groups for the treatment of pyelonephritis caused by 3GCephRE. However, all studies were at high risk of bias and provided low-certainty evidence due to very small sample sizes.",
                "None of the retrospective cohort studies comparing cephamycins and cefepime with carbapenems for the treatment of pyelonephritis caused by 3GCephRE found statistically significant differences between groups, with very small sample sizes and high risk of bias. The evidence for these antibiotics in the treatment of IAI caused by 3GCephRE is therefore of low-certainty.\n\nRegarding temocillin,",
                "Based on the RCT (Tango-II) study, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE.",
                "The level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is moderate.",
                "Based on the context provided, there is currently insufficient evidence on the comparative efficacy and safety of plazomicin versus colistin for the treatment of CRE infections. The available data comes from a single study that showed a lower all-cause mortality at 28 days with plazomicin combination therapy compared to colistin combination therapy, but the evidence is of very-low certainty due to the small sample size and the suspension of the study after",
                "Based on the evidence from the AIDA and OVERCOME trials, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. (p > 0.25 in both trials).",
                "Based on the available evidence, the clinical and microbiological efficacies of cefiderocol monotherapy and combination therapy in the treatment of CRE infections are similar. However, there is low-certainty evidence for the non-inferiority of cefiderocol compared to other antibiotics for MBL-producing CRE. There is no clinical experience evaluating the use of aztreonam monotherapy in the treatment of CRE infections,",
                "The retrospective cohort study reported higher clinical care (adjusted OR 2.63, 95% CI 1.31-5.30) and lower nephrotoxicity (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam compared with polymyxins or aminoglycosides",
                "The recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use a combination of two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combinations can be recommended or opposed.",
                "For patients with CRAB susceptible to sulbactam and HAP/VAP, the suggested treatment is ampicillin-sublactam. (conditional recommendation, low certainty of evidence)",
                "Based on the available evidence, we conclude on low-certainty evidence for the non-inferiority of cefiderocol compared to other antibiotics for MBL-producing CRE infections. However, there is limited information available to date, and we conditionally recommend against the use of cefiderocol for CRAB infections due to a lack of evidence for its efficacy and safety.",
                "There have been several observational studies assessing the combination of polymyxins and carbapenems for CRAB infections. Some of these studies showed a significant association between the use of the combination and improved survival or clinical cure [198, 235, 247]. However, it's important to note that many of these studies included patients treated with a polymyxin-carbapenem combination in a larger group of patients treated",
                "1. For severe infections caused by CRE susceptible only to polymyxin, aminoglycosides, tigecyline or fostomycin, or in the absence of new BLBLI, use more than one drug active in vitro.\n2. Avoid carbapenem-based combination therapy for CRE infections unless meropenem MIC is <= 8 mg/L.\n3. For non-severe or low-r",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epidemiology (",
                "Based on the context provided, the recommendation is for conditional use of targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery (conditional recommendation for use, low certainty of evidence).",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers.",
                "1. Postsurgical monitoring of antibiotic resistance, including CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n        2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n        3. Designing clinical trials in ESCR-E carriers undergoing high-risk surgical procedures, considering the",
                "Based on the current evidence, there is no recommendation for targeted PAP for CRE carriers before surgery. However, the knowledge of CRE colonization in high-risk patients, such as those undergoing transplant surgery, is relevant for infection control purposes and for the adaptation of postsurgical empirical treatment. Clinical trials are recommended to assess the impact of CRE rectal screening and the effectiveness, applicability, and safety of targeted PAP in CRE carriers undergoing",
                "It is a good practice to screen SOT recipients for CRAB before surgery, according to the local epidemiology (ungraded good practice statement). This can help inform infection control measures and guide postsurgical empirical treatment. The choice of screening methods and the timing of screening should be based on local work organization and integrated within antibiotic and diagnostic stewardship guidance.",
                "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in clinical trials.",
                "The suggested duration of PAP in transplant surgery other than renal transplant is 48-72 hours according to some expert recommendations. However, this may vary depending on the specific surgical scenario and the presence of risk factors for SSIs. It is important to note that there is currently no formal consensus on the optimal duration of PAP in transplant surgery, and further research is needed to investigate the clinical impact of shorter versus longer PAP durations.",
                "The risk of MDR-GNB infections in SOT recipients ranges from 3% to 53%, with the highest rates observed for intestinal, liver, and pancreas transplantation. Intra-abdominal infections, particularly in the early post-transplant period, are common in liver-transplant recipients (LTR), with a risk of ESBL and CRKP infections ranging from 6% to 13%",
                "We suggest rectal screening to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
                "The trial reported a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for ciprofloxacin PAP versus culture-based PAP. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers. However, the trial did not demonstrate a significant",
                "There is evidence suggesting an association between urinary colonization with MDR-GNB and an increased risk of postoperative infections in patients undergoing urologic surgery. However, the optimal approach to targeted preoperative antibiotic prophylaxis (PAP) based on preoperative cultures, including urinary cultures, is not well established and requires further research. The available evidence is limited, and there is a need for larger, prospective studies to evaluate the impact of",
                "A comprehensive approach to reducing SSIs involves a combination of antibiotic-based interventions and best surgical practices. This includes minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, managing patient comorbidities, enhancing surveillance protocols, promoting adherence to guidelines, and implementing stewardship initiatives to monitor and contain the consequences of new prescription patterns. The optimization of antibiotic-based interventions should focus not only on",
                "1. Standard operating procedures (SOPs) for sampling site technique and microbiological methods should be established and followed consistently to minimize contamination and ensure accurate results.\n        2. SOPs for sampling site technique should include proper hand hygiene, use of sterile equipment, and appropriate collection and transport of specimens.\n        3. SOPs for microbiological methods should include appropriate culture media, incubation conditions, and identification techniques to ensure accurate detection and",
                "1. Rectal culture results should be considered when choosing targeted PAP for CRE infections.\n2. The limited number of options available for the treatment of CRE infections should be taken into account to avoid using novel compounds that may be required for the treatment of postsurgical infections.\n3. Resistance monitoring should be performed through detection of MDR-CNB carriage after surgery and to detect emerging resistance to the regimens used for targeted PAP.\n4",
                "Knowing the colonization status of a patient before solid organ transplantation (SOT) is essential for early implementation of infection control procedures. This information can help reduce the risk of intra-hospital and community spreading of multidrug-resistant bacteria (MDR-GNB), including carbapenem-resistant Enterobacterales (CRE), and inform contact precautions during treatment of postoperative infections."
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.10426927455870987,
                    "2_gram": 0.17232945312043874,
                    "3_gram": 0.12203449066382968,
                    "4_gram": 0.08598788681468703
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.23668217296509428,
                        "recall": 0.4109030657231275,
                        "fmeasure": 0.285740394312968
                    },
                    "rouge_L": {
                        "precision": 0.15572278316466392,
                        "recall": 0.2809290035071148,
                        "fmeasure": 0.1908752053324701
                    }
                },
                "METEOR": 0.23717818182947348,
                "BERTScore": {
                    "Precision": -0.003,
                    "Recall": 0.171,
                    "F1_measure": 0.083
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.11141463788088923,
                    "2_gram": 0.18204904662284616,
                    "3_gram": 0.13031715085607568,
                    "4_gram": 0.09079129596816363
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.24730519574032211,
                        "recall": 0.4196049847717524,
                        "fmeasure": 0.2914223958282858
                    },
                    "rouge_L": {
                        "precision": 0.17372168561673687,
                        "recall": 0.2921140135388925,
                        "fmeasure": 0.2044809352091253
                    }
                },
                "METEOR": 0.2426199338470025,
                "BERTScore": {
                    "Precision": 0.04,
                    "Recall": 0.216,
                    "F1_measure": 0.127
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.12026339387616636,
                    "2_gram": 0.22664973527968538,
                    "3_gram": 0.2200485274950356,
                    "4_gram": 0.17951259661788438
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.4110135434765301,
                        "recall": 0.7154715078530806,
                        "fmeasure": 0.5005554849727483
                    },
                    "rouge_L": {
                        "precision": 0.3234102791321041,
                        "recall": 0.5684399684061421,
                        "fmeasure": 0.3962993140260923
                    }
                },
                "METEOR": 0.49990001656962246,
                "BERTScore": {
                    "Precision": 0.283,
                    "Recall": 0.533,
                    "F1_measure": 0.404
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.15118710303091384,
                    "2_gram": 0.2700172632192454,
                    "3_gram": 0.26087175051417616,
                    "4_gram": 0.2141891613664425
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.48000643151680406,
                        "recall": 0.7000824374161734,
                        "fmeasure": 0.537051096843609
                    },
                    "rouge_L": {
                        "precision": 0.3949469063637234,
                        "recall": 0.579375939356798,
                        "fmeasure": 0.44330939070468456
                    }
                },
                "METEOR": 0.5047606664432696,
                "BERTScore": {
                    "Precision": 0.358,
                    "Recall": 0.544,
                    "F1_measure": 0.448
                }
            }
        }
    },
    {
        "parameters": {
            "embedding model": "NeuML/pubmedbert-base-embeddings",
            "llm": "microsoft/Phi-3-mini-128k-instruct",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 256,
            "overlap": 25,
            "top_k": 5,
            "max new tokens": 100,
            "re-ranking": 0,
            "top_n": 0
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the studies evaluating quinolones as a treatment option for 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "The studies found limited evidence on targeted quinolone therapy for 3GCephRE BSI, with one study reporting an association between quinolone treatment and lower mortality, but the analysis was limited by small sample sizes and potential biases, and therefore, there is no direct evidence to support the use of quinolones for targeted therapy.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                " The question seems to be referring to a specific type of cancer treatment, but the terms \"BSI,\" \"severe infection,\" and \"3GCephRE\" are not standard in medical terminology. It's possible that there's a mix-up or abbreviation that's not widely recognized.\n\nHowever, I can provide information on targeted therapy for a common type of cancer that might be relevant to your question:\n\nTargeted therapy is a",
                " The evidence on the treatment of infections caused by 3GCephRE (presumably a typo or a specific class of bacteria) is organized in a systematic and comprehensive manner to ensure that healthcare professionals and researchers can access and utilize the information effectively. Here's an overview of how this evidence is typically organized:\n\n1. Systematic reviews and meta-analyses: These are high-level evidence sources that summarize and analyze",
                " The studies evaluating quinolones as a treatment option for patients with multidrug-resistant Gram-negative bacterial bloodstream infections (3GCephRE BSI) have shown mixed results. Some studies suggest that quinolones, particularly fluoroquinolones, can be effective against certain multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherich",
                " I'm sorry, but it seems there might be a misunderstanding or typo in the question. \"3GCephRE\" does not correspond to any known antibiotic or bacterial strain. It's possible that the intended reference was to \"E. coli\" or another bacterium commonly associated with pyelonephritis, which is a type of urinary tract infection that affects the kidneys.\n\nAssuming the question is",
                " I'm sorry, but it seems there might be a misunderstanding or typo in the question. \"3GCephRE\" does not correspond to any known antibiotic or bacterial strain. It's possible that the intended reference was to a specific antibiotic or a group of antibiotics, but without the correct name, it's challenging to provide a specific answer.\n\nHowever, I can provide a general overview of how Random",
                " The level of evidence for the advantage of meropenem-vaborbactam over the best available treatment for susceptible carbapenem-resistant Enterobacteriaceae (CRE) can be categorized based on the strength and quality of clinical research. As of my last update in 2023, the evidence primarily comes from retrospective studies, case series, and a few randomized controlled trials (RCTs).\n\n1. **",
                " The level of evidence for the advantage of aminoglycosides over tigecycline for the treatment of complicated urinary tract infections (cUTI) is not definitive and can vary based on the specific context and patient population. Clinical trials and meta-analyses are essential to determine the efficacy and safety of these antibiotics.\n\nAminoglycosides, such as gentamicin, tobramyc",
                " As of my last update in early 2023, plazomicin has been studied as a potential alternative to colistin for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections. Plazomicin is a next-generation aminoglycoside with a broader spectrum of activity and improved pharmacokinetics, which may overcome some of the limitations associated with colistin, such as ne",
                " To answer this question, a systematic review and meta-analysis of the available literature comparing the 28-day mortality rates between colistin monotherapy and colistin-carbapenem combination therapy in patients with CRE (Carbapenem-Resistant Enterobacteriaceae) infections would be required.\n\n\nA comprehensive search of databases such as PubMed, Embase, and the Cochrane Library would be conducted",
                " Cefiderocol is a siderophore cephalosporin that has been developed to treat infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections comes from clinical trials and studies that compare the efficacy, safety, and resistance development of these treatment strategies.\n\n1. Efficacy",
                " I'm sorry, but as of my last update in April 2023, I don't have access to real-time databases or the ability to retrieve or summarize specific studies or their results. To find the results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with multidrug-resistant (MDR) or extensively drug-resistant",
                " The treatment of severe infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA) with polymyxins, aminoglycosides, or fosfomycin should be approached with caution and typically involves a combination of antimicrobial agents to achieve synergistic effects and to prevent the development of further resistance.\n\n1. Polymyxins: Polymyxins, such as colistin",
                " The treatment for patients with CRAB (Calcium elevation, Renal failure, Anemia, and Bone lesions) susceptible to sulbactam and HAP/VAP (Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia) should be individualized based on the patient's specific condition, microbial susceptibility, and local antibiotic resistance patterns. However, a general approach can be suggested:",
                " Cefiderocol is a siderophore cephalosporin that has shown promising results in treating carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Its efficacy is attributed to its unique mechanism of action, which involves binding to iron and being actively transported across the bacterial outer membrane. This allows cefiderocol to penetrate the bacterial cell wall and exert",
                " As of my last update in April 2023, the combination therapy of polymyxins and carbapenems for the treatment of CRAB (Catheter-Related Bloodstream Infections) caused by multidrug-resistant organisms has been a subject of interest due to the increasing prevalence of antibiotic resistance. However, the evidence from observational studies on the effectiveness of this combination therapy is limited and somewhat mixed.",
                " The general principles for antibiotic treatment in patients with Chronic Rhinosinusitis (CRS) with nasal polyps (CR-GNB) infections are as follows:\n\n\n1. **Diagnosis and Identification**: Accurate diagnosis of CR-GNB is essential. This involves a thorough clinical evaluation, including nasal endoscopy and imaging studies like CT scans. Identification of the causative organisms through cult",
                " The suggested screening approach for patients undergoing colorectal and liver transplant surgery involves a comprehensive evaluation to assess the risk of colorectal cancer (CRC) and hepatocellular carcinoma (HCC), which are the primary cancers associated with these transplants. The screening should be tailored to the individual patient's risk factors, including age, family history, and underlying liver disease.\n\nFor colorectal",
                " The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended Spectrum \u03b2-Lactamase-producing Enterobacteriaceae (ESCR-E) undergoing colorectal surgery is to administer a third-generation cephalosporin or a carbapenem. This is due to the high risk of infection with ESCR-E organisms, which are resist",
                " The treatment of extensively drug-resistant (XDR) bacteria requires careful consideration due to the limited options available. Antibiotics reserved for the treatment of XDR bacteria and not used routinely for targeted PAP (prophylaxis against infection) in Extended Spectrum \u03b2-Lactamase (ESBL)-producing carriers (ESCR-E) are typically those with a narrow spectrum of activity and high efficacy",
                " When designing research protocols to investigate the impact of targeted prophylactic antibiotic (PAP) therapy on reducing post-transplant infections among Extended Criteria Donor (ESCR)-E colonized Solid Organ Transplant (SOT) candidates, it is essential to include several key components to ensure the study's validity, reliability, and ethical integrity. Here are the recommended elements to be included:\n\n1. **",
                " Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. However, it is essential to consider the following points:\n\n1. Individual patient assessment: The decision to administer PAP should be based on a thorough evaluation of the patient's medical history, the type of surgery, the",
                " A good practice for screening SOT (Solid Organ Transplant) recipients for CANCER (CRAB) before surgery involves a comprehensive approach that includes the following steps:\n\n\n1. **Pre-transplant Evaluation:**\n\n   - Conduct a thorough medical history and physical examination focusing on signs and symptoms of malignancy.\n\n   - Review previous imaging studies and pathology reports for any evidence of cancer.",
                " As of my last update in April 2023, there isn't a specific panel of experts or a universally recognized set of guidelines that directly suggests the design of clinical trials for investigating CRAB (Cytomegalovirus, Aspergillus, Bacterial, and other rare infections) colonization and targeted PAP (Potential Antiparasitic) therapies. However, I can",
                " Perioperative antibiotic prophylaxis (PAP) is a critical component in transplant surgery to prevent surgical site infections (SSIs). The duration of PAP in transplant surgery, other than renal transplant, is generally tailored to the type of surgery, the patient's risk factors, and the institution's protocols. However, there are some general guidelines that can be followed.\n\nFor most trans",
                " Multidrug-resistant Gram-Negative Bacteria (MDR-GNB) infections in Solid Organ Transplant (SOT) recipients are a significant clinical concern due to the high risk of morbidity and mortality associated with these infections. The risk of MDR-GNB infections in SOT recipients is influenced by several factors, including the type of organ transplanted, the immunosuppressive therapy",
                " The suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) involves a combination of clinical, microbiological, and molecular methods. Here is a step-by-step approach:\n\n1. Obtain a detailed medical history: Gather information about the patient's previous antibiotic use,",
                " As of my last update in April 2023, I don't have access to real-time databases or the ability to pull up specific studies or trial results. However, I can provide you with a general overview of what such a study might entail and the potential outcomes based on existing knowledge in the field.\n\nA randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (post-thor",
                " The association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery is a significant concern in the field of urology and infectious diseases. MDR-GNB are bacteria that have developed resistance to multiple classes of antibiotics, making them challenging to treat. These bacteria can colonize the ur",
                " Reducing surgical site infections (SSIs) requires a comprehensive approach that involves multiple strategies and the collaboration of a multidisciplinary team. Here are the key components of a comprehensive approach to reduce SSIs:\n\n1. Preoperative measures:\n   a. Patient assessment: Evaluate the patient's medical history, comorbidities, and risk factors for SSIs.\n   b. Optimization of the patient",
                " Standard Operating Procedures (SOPs) for sampling site technique and microbiological methods are essential for ensuring the consistency, reliability, and validity of microbiological analyses. Here are some general recommendations for developing SOPs in these areas:\n\n1. Define the purpose and scope: Clearly state the objectives, scope, and limitations of the SOPs. Identify the specific microbiological methods and sampling site techniques to be covered",
                " When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered:\n\n1. Patient factors: Age, comorbidities, allergies, renal and hepatic function, and previous antibiotic exposure should be taken into account.\n\n2. Infection factors: The site and severity",
                " Understanding the colonization status of a patient before solid organ transplantation (SOT) is crucial for several reasons:\n\n\n1. **Infection Risk**: The colonization of a patient with certain microorganisms can significantly increase the risk of post-transplant infections. These infections can be life-threatening and can compromise the success of the transplant.\n\n\n2. **Antibiotic Prophylaxis"
            ],
            "additional prompt / no context": [
                " The recommended targeted therapy for patients with BSI (Bacteremia and Septicemia) and severe infection due to 3GCephRE (a hypothetical antibiotic) would depend on the specific bacterial strain and its resistance profile. However, in general, targeted therapy may include the use of newer antibiotics such as ceftolozane/tazobactam, ceftazidime/avibactam",
                " The evidence on treatment of infections caused by 3GCephRE (a hypothetical antibiotic class) is organized into clinical trials, meta-analyses, and systematic reviews that evaluate the efficacy, safety, and resistance patterns of these antibiotics.",
                " The studies found that quinolones can be an effective treatment option for patients with 3GCephRE BSI, particularly in cases where the bacteria are susceptible to these antibiotics.",
                " Cephamycins and cefepime showed similar efficacy to carbapenems in treating pyelonephritis caused by 3GCephRE.",
                " The RCTs found that certain antibiotics, such as piperacillin-tazobactam, cefoperazone-sulbactam, and meropenem, were effective in treating IAI caused by 3GCephRE.",
                " Level of evidence: Level II (Randomized Controlled Trials)",
                " Level of evidence: Level C (Case series or poor-quality cohort studies)",
                " Yes, there is sufficient evidence that plazomicin has a higher efficacy and safety profile compared to colistin for the treatment of CRE infections.",
                " Yes, studies have shown that colistin-carbapenem combination therapy can reduce 28-day mortality compared to colistin monotherapy in patients with CRE infections.",
                " Cefiderocol monotherapy has shown efficacy in treating CRE infections, with studies like the CREthoric trial demonstrating its effectiveness. However, combination therapy may be preferred in certain cases to prevent resistance and improve outcomes. The choice between monotherapy and combination therapy should be based on individual patient factors, local resistance patterns, and clinical guidelines.",
                " The retrospective cohort study found that ceftolozane-tazobactam had a higher efficacy rate compared to polymyxins or aminoglycosides in treating MDR/XDR P. aeruginosa mixed infections.",
                " The treatment of severe infections caused by CRPA (Cryptosporidium-related parasitic infections) with polymyxins, aminoglycosides, or fosfomycin is not standard, as these antimicrobials are not typically used for treating parasitic infections. CRPA is usually treated with antiparasitic medications such as nitazoxanide or paromomyc",
                " The suggested treatment for patients with CRAB (Catheter-Related Bacteremia, Acute Pyelonephritis, Bacteremia, and Ventilator-Associated Pneumonia) susceptible to sulbactam and HAP/VAP (Hospital-Acquired and Ventilator-Associated Pneumonia) is a combination of antibiotics that includes a beta-lactam antibiotic such as piperacill",
                " Cefiderocol has shown high efficacy in treating CRAB infections, particularly in cases resistant to other antibiotics. It is a siderophore cephalosporin that binds to iron and is actively transported across the outer membrane of Gram-negative bacteria, including CRAB strains. Clinical trials have demonstrated its effectiveness, especially in patients with infections caused by carbapenem-res",
                " Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB infections, particularly in cases of multi-drug resistant organisms. However, the evidence is limited, and more randomized controlled trials are needed to confirm these findings.",
                " The general principles for antibiotic treatment in patients with CR-GNB (chronic relapsing neutrophilic dermatosis) infections include:\n\n1. Confirm diagnosis through biopsy and culture.\n2. Identify and treat any underlying infection or inflammatory condition.\n3. Use broad-spectrum antibiotics if an infection is suspected.\n4. Consider antifungal or antiviral",
                " The suggested screening approach for patients undergoing colorectal and liver transplant surgery includes preoperative evaluation for hepatitis B and C, HIV, and other infectious diseases. Postoperatively, patients should be monitored for signs of infection, graft rejection, and liver function. Regular screening for colorectal cancer should be considered based on individual risk factors.",
                " The recommendation for perioperative antibiotic prophylaxis in patients colonized with ESCR-E (Extended Spectrum Coagulase-negative Resistant Enterobacteriaceae) undergoing colorectal surgery is to administer a first-generation cephalosporin or a carbapenem within 60 minutes before the surgical incision.",
                " Colistin and Tigecycline",
                " Include a detailed description of the PAP targeting strategy, patient selection criteria, infection surveillance methods, and statistical analysis plan.",
                " Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis for patients colonized with CRE before surgery, but it should be based on current guidelines and local antibiotic resistance patterns.",
                " Perform a complete blood count (CBC) with differential, serum protein electrophoresis (SPEP), and urine protein electrophoresis (UPEP) to screen for CRAB (Calcium, Renal function, Anemia, and Bone lesions) before SOT recipient surgery.",
                " The panel suggests designing randomized controlled trials (RCTs) to investigate CRAB colonization and targeted PAP.",
                " The suggested duration of perioperative antibiotic prophylaxis (PAP) in transplant surgery varies depending on the type of surgery and the patient's risk factors. Generally, PAP is recommended for 24 hours for most transplant surgeries. However, for high-risk patients or surgeries with a higher risk of infection, PAP may be extended up to 7 days. It's essential to follow the specific",
                " The risk of MDR-GNB (multidrug-resistant Gram-negative bacteria) infections in solid organ transplant recipients is significant due to their immunocompromised state and the use of broad-spectrum antibiotics. Consequences include increased morbidity and mortality, longer hospital stays, and higher healthcare costs.",
                " Perform a urine culture and sensitivity test before the procedure.",
                " The outcome of such a trial would likely show that ciprofloxacin PAP is less effective in FQR carriers compared to culture-based PAP, leading to a higher rate of treatment failure in the ciprofloxacin PAP group.",
                " Urinary colonization with MDR-GNB is associated with an increased risk of postoperative infections in patients undergoing urologic surgery.",
                " A comprehensive approach to reduce SSIs includes:\n\n\n1. Preoperative measures:\n\n   - Screening and treating patients for infections.\n\n   - Optimizing patient health and nutrition.\n\n   - Administering prophylactic antibiotics appropriately.\n\n\n2. Intraoperative measures:\n\n   - Maintaining a sterile environment.\n\n   - Using proper surgical techniques and",
                " Adherence to standardized protocols for sample collection, labeling, transport, and processing is recommended. Utilize aseptic techniques to avoid contamination. Employ appropriate culture media and incubation conditions based on the suspected pathogens. Perform quality control with known positive and negative controls.",
                " Consider the patient's allergy history, local antibiogram data, and the specific CRE species involved.",
                " To prevent post-transplant infections and rejection."
            ],
            "no additional prompt / context": [
                " The recommended targeted therapy for patients with bloodstream infection (BSI) and severe infection due to third-generation cephalosporin-resistant Enterobacteriaceae (3GCephRE) is a carbapenem, specifically imipenem or meropenem. This recommendation is based on a strong recommendation for use with moderate certainty of evidence.",
                " The evidence on treatment of infections caused by 3GCephRE is organized based on clinical syndromes, specifically Bloodstream Infections (BSI), Urinary Tract Infections (UTI), Pneumonia, and Intra-abdominal Infections (IAI). The studies addressing these syndromes are described in Table 3.",
                " The studies evaluating quinolones as a treatment option for 3GCephRE BSI found mixed results. In one study, quinolones were associated with lower mortality when used as targeted therapy for BSI of urinary tract source, as per an adjusted analysis [67]. However, the quinolone group in all studies was very small (4-24 patients), and the observational design of these studies makes it difficult to directly analyze",
                " The studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE found no statistically significant differences between the treatment groups. However, it's important to note that these studies were small in size, ranging from 10 to 23 patients, and were at high risk of bias. Therefore, the evidence provided was of low certainty.",
                " The provided context does not contain specific findings from RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE. The text mentions that the evidence on treatment of infections caused by 3GCephRE is provided by clinical syndrome, including IAI, but it does not provide detailed results or conclusions from RCTs for this specific condition. The text suggests",
                " The level of evidence for the advantage of meropenem-vaborbactam over best available treatment (BAT) for susceptible carbapenem-resistant Enterobacteriaceae (CRE) is moderate. This conclusion is based on a small randomized controlled trial (RCT) that included 47 patients (randomized 2:1). The study found significantly improved cure rates at the end of treatment with meropenem-vaborbact",
                " The level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is judged as moderate. This conclusion is based on the available studies, which have shown that tigecycline was inferior to aminoglycosides for cUTI caused by CRE. However, there is insufficient evidence for other comparisons and other sources of infection.",
                " Based on the context provided, there is currently insufficient evidence to compare the efficacy of plazomicin and colistin for the treatment of CRE infections. The available results from a study mentioned in the context showed that all-cause mortality at 28 days was 8/20 with colistin combination therapy versus 2/17 with plazomicin combination therapy. However, the study was suspended after 2 years due",
                " Based on the information provided, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. The AIDA trial showed a mortality rate of 35% for colistin monotherapy compared to 21% for the combination therapy (p = 0.24), and the OVERCOME trial showed",
                " The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is not explicitly provided in the context above. However, the context does mention that a subgroup analysis of patients with MBL-producing CRE infections showed statistically non-significant higher cure and microbiological eradication rates for cefiderocol compared to BAT (Beta-lactam/beta-lactamase",
                " The retrospective cohort study found that treatment with ceftolozane-tazobactam was associated with higher clinical care (adjusted odds ratio [OR] 2.63, 95% confidence interval [CI] 1.31-5.30) and lower nephrotoxicity (adjusted odds ratio [OR] 0.08, 95% CI 0.03-",
                " The recommendation for treating severe infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA) with polymyxins, aminoglycosides, or fosfomycin is to use two in vitro active drugs as part of combination therapy. This suggestion is based on a conditional recommendation for use with very low certainty of evidence. No specific combinations are recommended or against, and the choice should be made on an individual",
                " The suggested treatment for patients with CRAB (Carbapenem-Resistant Acinetobacter baumannii) susceptible to sulbactam and HAP/VAP (Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia) is ampicillin-sulbactam. This recommendation is based on a retrospective study that included 167 patients with different CRAB infections, mostly in IC",
                " The efficacy of cefiderocol compared to other antibiotics in treating CRAB (carbapenem-resistant Acinetobacter baumannii) infections is not clearly established based on the available evidence. The CREDIBLE trial, which compared cefiderocol with BAT (bacteriocin-producing A. baumannii) for CR-GNB infections, showed no significant advantage of cef",
                " Observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections have shown mixed results. Some studies have reported a significant association between the use of this combination therapy and improved survival or clinical cure rates compared to polymyxin monotherapy. For instance, studies by [198, 235, 247] have suggested that the combination therapy could be beneficial. However",
                " The general principles for antibiotic treatment in patients with CR-GNB (Carbapenem-Resistant Gram-Negative Bacteria) infections, as outlined in the provided context, are as follows:\n\n1. Treatment with more than one drug active in vitro: In cases of severe infections caused by CR-GNB, it is recommended to use a combination of more than one drug that is active against the bacter",
                " The suggested screening approach for patients undergoing colorectal and liver transplant surgery is to implement rectal screening to identify carriers of Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) before surgery. This recommendation is based on the local epidemiology of ESCR-E colonization and infection among patients admitted or transferred to the surgical wards. The choice between targeted and universal",
                " The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E (Extended Spectrum Carbapenem-Resistant Enterobacteriaceae) undergoing colorectal surgery is to conditionally recommend targeted PAP. This means that the use of targeted PAP should be considered based on the local epidemiology of ESCR-E carriage and the specific circumstances of the surg",
                " The antibiotics that should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E (Extensively Drug-Resistant Enterobacterales) carriers include novel molecules such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, cefiderocol, and im",
                " Research protocols investigating the impact of targeted postoperative antibiotic prophylaxis (PAP) in reducing post-transplant infections among extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) colonized solid organ transplant (SOT) candidates should include the following elements:\n\n1. Monitoring of antibiotic resistance: The protocol should include regular monitoring of antibiotic resistance",
                " Based on the information provided, a conditional recommendation can be issued for implementing rectal screening to identify CRE carriers before liver transplant surgery according to the local epidemiology. This recommendation is given with a low certainty of evidence, indicating that the available data are limited and the certainty of the recommendation is not high. The recommendation is made with the understanding that the knowledge of CRE colonization in high-risk patients, such as those receiving transplant surgery",
                " A good practice for screening SOT recipients for CRAB before surgery, according to the panel's recommendations, is to conduct screening based on the local epidemiology. This means that the decision to screen should take into account the prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards in the specific healthcare setting. The panel suggests considering a prevalence threshold of >=10% as a cut-off",
                " The panel suggests designing clinical trials to compare the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in these clinical trials.",
                " In transplant surgery other than renal transplant, the suggested duration of PAP (prophylactic antibiotic administration) is 48-72 hours. This recommendation is based on expert opinion and the lack of formal consensus due to the absence of comparative trials. The duration may vary depending on the type of transplant, with specific durations suggested for different organ transplants. For example, a shorter duration of PAP (<24 hours",
                " MDR-GNB infections pose a significant risk to solid organ transplant (SOT) recipients, with the prevalence of these infections varying depending on the type of transplant. The risk of MDR-GNB infections is particularly high in lung transplant recipients, with rates ranging from 6% to 13% for extended spectrum carbapenem-resistant Enterobacteriaceae (ESCR-E) and",
                " The suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is rectal screening. This recommendation is based on the association between FQR-E colonization and increased rates of post-TRUSPB infectious complications. The European Association of Urology (EAU) guidelines",
                " The randomized, non-blinded, multicenter trial compared ciprofloxacin prophylactic antibiotic (PAP) versus culture-based PAP in patients undergoing transrectal ultrasound-guided prostate biopsy (TRUSPB). The study included 1288 patients, with 15.8% identified as fluoroquinolone-resistant (FQR) carriers.",
                " The association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery is significant. Studies have shown that patients with urinary colonization are at a higher risk of developing postoperative infections compared to noncolonized patients. Specifically, a small, prospective single-center study reported that 22% of ESCR-E carri",
                " The comprehensive approach required to reduce surgical site infections (SSIs) involves a multifaceted strategy that includes both antibiotic-based interventions and best surgical practices. This approach should focus on the following key elements:\n\n1. Targeted antibiotic prophylaxis (PAP): The choice of targeted PAP should be based on the local epidemiology of CRAB colonization and infection among patients admitted or",
                " The context provided does not explicitly detail the recommendations for standard operating procedures (SOPs) related to sampling site technique and microbiological methods. However, it does emphasize the importance of careful assessment of local prevalence of ESCR-E colonization and infection among patients admitted or transferred to the surgical wards when considering changes in screening procedures. It also suggests that the choice of targeted versus universal screening should be based on the local work organization and integrated",
                " When choosing targeted perioperative antibiotic prophylaxis (PAP) for CRE infections, several factors should be considered:\n\n1. Local epidemiology: The prevalence of CRE in the local population and the specific risk factors for CRE infections should be taken into account. This information can help determine the need for CRE screening and the selection of appropriate targeted PAP regimens.\n\n2. Rect",
                " Knowing the colonization status of a patient before solid organ transplantation (SOT) is crucial for several reasons. Firstly, it allows for the early implementation of infection control procedures, which can reduce the risk of intra-hospital and community spreading of infections. This is particularly important in the context of multidrug-resistant organisms (MDROs), such as carbapenem-resistant Enterobacterales (CRE), Ext"
            ],
            "additional prompt / context": [
                " The recommended targeted therapy for patients with bloodstream infection (BSI) and severe infection due to 3GCephRE is a carbapenem, specifically imipenem or meropenem.",
                " The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, specifically for bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI). The studies are categorized into different recommendations based on the severity of the infection and the patient's condition.",
                " The studies evaluating quinolones as a treatment option for 3GCephRE BSI found that quinolones were not significantly different from carbapenems or piperacillin-tazobactam in terms of mortality. However, the evidence was very low certainty due to the small sample sizes and observational study design.",
                " The studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE found no statistically significant differences between the groups. However, the sample sizes were small (ranging from 10 to 23 patients), and all studies were at high risk of bias. This provided low-certainty evidence for the use of cephamycins and cefepime",
                " The context provided does not include specific findings from RCTs evaluating antibiotics for the treatment of IAI caused by 3GCephRE. It mentions that the evidence on treatment of infections caused by 3GCephRE is provided by clinical syndrome, including IAI, but does not provide details on the results of RCTs for this specific condition.",
                " The level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE is moderate. This conclusion is based on a small study with 47 patients, which showed significantly improved cure rates at the end of treatment for the meropenem-vaborbactam group compared to the best available treatment group. However, the certainty of this evidence is considered low due to the observational study design and the small sample size",
                " The level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is judged as moderate.",
                " No, there is currently insufficient evidence comparing plazomicin to colistin for the treatment of CRE infections. The available results from a study showed similar all-cause mortality rates at 28 days between colistin combination therapy and plazomicin combination therapy for patients with baseline monomicrobial CRPA infections. However, the study was suspended due to enrollment difficulties, and more data are needed to make",
                " No, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections based on the AIDA and OVERCOME trials.",
                " The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is not explicitly provided in the context above. However, it is mentioned that clinical and microbiological efficacies of cefiderocol versus other antibiotics were similar. A subgroup analysis showed a non-significant higher cure and microbiological eradication rates for cefiderocol in patients with MBL-producing C",
                " The retrospective cohort study found that clinical care was higher with ceftolozane-tazobactam compared to polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections. The adjusted odds ratio (OR) for better clinical care was 2.63 (95% CI 1.31-5.30). Additionally, the study reported lower ne",
                " The recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combinations are recommended or against.",
                " For patients with CRAB susceptible to sulbactam and HAP/VAP, the suggested treatment is ampicillin-sulbactam. This recommendation is based on a retrospective study that compared colistin or polymyxin B with ampicillin-sulbactam, with additional antibiotics not active in vitro in both groups. The study found that mortality at the end of treatment was significantly higher in the polym",
                " Cefiderocol has shown non-inferiority to other antibiotics in treating MBL-producing CRE infections, but there is no strong evidence supporting its superiority. In the CREDIBLE trial, cefiderocol had a higher mortality rate compared to BAT for CRAB infections. However, in the APEKS-NP trial, cefiderocol showed similar mortality, clinical, and",
                " Observational studies have shown mixed results regarding the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections. Some studies have demonstrated a significant association between the use of this combination therapy and improved survival or clinical cure when compared to polymyxin monotherapy. However, other studies did not find a significant difference. It's important to note that these observational studies often included patients treated with various combination therapies,",
                " The general principles for antibiotic treatment in patients with CR-GNB infections include:\n\n1. Use of combination therapy with more than one drug active in vitro, especially in severe infections.\n2. Avoidance of carbapenem-based combination therapy unless the meropenem MIC is <= 8 mg/L, where high-dose extended-infusion meropenem may be used as part of combination ther",
                " The suggested screening approach for patients undergoing colorectal and liver transplant surgery is to implement rectal screening to identify carriers of Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) before surgery. This recommendation is based on the local epidemiology of ESCR-E colonization and infection. The screening should be considered for all SOT recipients according to the local epide",
                " The recommendation is to conditionally use targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery. This recommendation is based on low certainty of evidence from studies that showed an increased rate of postoperative infections and SSIs in ESCR-E carriers compared to noncarriers.",
                " The antibiotics that should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers include novel molecules such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam. These are considered reserve ant",
                " Research protocols should include monitoring of antibiotic resistance, specifically CRE colonization through rectal cultures, and reporting antimicrobial susceptibility results according to the European Committee on Antimicrobial Susceptibility Testing guidelines.",
                " No, a recommendation cannot be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery based on the current evidence. The studies available have not provided data on adverse events or emergence of antibiotic resistance following targeted PAP in CRE carriers undergoing transplant surgery. Therefore, conclusions on the effectiveness",
                " A good practice for screening SOT recipients for CRAB before surgery is to screen all SOT recipients according to the local epidemiology. This approach should be integrated within antibiotic and diagnostic stewardship guidance. The implementation of screening procedures should be based on a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards.",
                " The panel suggests designing clinical trials to compare the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in these trials.",
                " The suggested duration of PAP in transplant surgery other than renal transplant is 48-72 hours.",
                " MDR-GNB infections pose a significant risk to solid organ transplant (SOT) recipients, with rates varying depending on the type of transplant and geographic location. Intestinal, liver, and pancreas transplant recipients are at the highest risk. The consequences of these infections are severe, often leading to increased morbidity and mortality. Post-transplant infections caused by MDR-GNB are associated with higher mort",
                " The suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is rectal screening. This recommendation is based on the moderate certainty of evidence and is considered a conditional recommendation. The screening aims to identify patients who are colonized with FQR-E to potentially modify the prophylactic ant",
                " The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate when comparing ciprofloxacin PAP to culture-based PAP. Notably, FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
                " The association between urinary colonization with MDR-GNB and postoperative infections in patients undergoing urologic surgery is significant. Studies have shown that patients with urinary colonization are at a higher risk of developing postoperative infections compared to noncolonized patients. Specifically, a small, prospective single-center study found that 22% of ESCR-E carriers received targeted PAP and developed postoperative infections",
                " The comprehensive approach to reduce SSIs involves coordinated actions such as decolonization, active surveillance, and stewardship measures. It also includes optimizing antibiotic-based interventions, promoting a multidisciplinary approach, and implementing best surgical practices. These practices include minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, and managing patient comorbidities.",
                " The context provided does not specify standard operating procedures (SOPs) for sampling site technique and microbiological methods. However, it is generally recommended that SOPs for these procedures should be evidence-based, standardized, and integrated within antibiotic and diagnostic stewardship guidance. The choice between targeted and universal screening should be based on local epidemiology and work organization. It is also important to consider the knowledge of the colonization status of the patient before",
                " When choosing targeted perioperative antibiotic prophylaxis (PAP) for CRE infections, consider the following:\n\n1. Local epidemiology: Tailor the PAP strategy based on the prevalence of CRE in the local population.\n2. Rectal screening: Implement rectal screening to identify CRE carriers before surgery, especially in high-risk procedures like liver transplant surgery.",
                " Knowing the colonization status of a patient before SOT is crucial for several reasons. Firstly, it helps in early implementation of infection control procedures, reducing the risk of intra-hospital and community spreading. Secondly, it allows for the implementation of targeted antibiotic prophylaxis, which can be more effective and reduce the risk of antibiotic resistance. Lastly, it aids in the early detection and management of potential post-trans"
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.1088473882369812,
                    "2_gram": 0.178305007471309,
                    "3_gram": 0.1240374471841939,
                    "4_gram": 0.08514447609357859
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.23176734085775652,
                        "recall": 0.4107646675810394,
                        "fmeasure": 0.2835333998617834
                    },
                    "rouge_L": {
                        "precision": 0.16555504290289813,
                        "recall": 0.30785210766774507,
                        "fmeasure": 0.20636450676928808
                    }
                },
                "METEOR": 0.22999258626625801,
                "BERTScore": {
                    "Precision": 0.013,
                    "Recall": 0.151,
                    "F1_measure": 0.081
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.236768642609543,
                    "2_gram": 0.28346985803017194,
                    "3_gram": 0.1910561012460386,
                    "4_gram": 0.13375662444525888
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.34553796791583463,
                        "recall": 0.3001404587973551,
                        "fmeasure": 0.279628118729639
                    },
                    "rouge_L": {
                        "precision": 0.2701358805412013,
                        "recall": 0.22722074858300123,
                        "fmeasure": 0.21307049980262727
                    }
                },
                "METEOR": 0.18648413272011577,
                "BERTScore": {
                    "Precision": 0.159,
                    "Recall": 0.141,
                    "F1_measure": 0.149
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.11777346412043976,
                    "2_gram": 0.2128756613636173,
                    "3_gram": 0.19281718179477614,
                    "4_gram": 0.1532102749253836
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3726260885264727,
                        "recall": 0.6385828609792723,
                        "fmeasure": 0.4461496241829253
                    },
                    "rouge_L": {
                        "precision": 0.27298849509209355,
                        "recall": 0.4758204748702343,
                        "fmeasure": 0.329018387343423
                    }
                },
                "METEOR": 0.38796260505978686,
                "BERTScore": {
                    "Precision": 0.201,
                    "Recall": 0.411,
                    "F1_measure": 0.303
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.14134124739176646,
                    "2_gram": 0.2502573677022414,
                    "3_gram": 0.23846009012742891,
                    "4_gram": 0.19494408507328642
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.45531997241668376,
                        "recall": 0.6786722337350691,
                        "fmeasure": 0.5136900041731046
                    },
                    "rouge_L": {
                        "precision": 0.35321376965071183,
                        "recall": 0.5281383747628888,
                        "fmeasure": 0.398546527612028
                    }
                },
                "METEOR": 0.4477359869759507,
                "BERTScore": {
                    "Precision": 0.376,
                    "Recall": 0.511,
                    "F1_measure": 0.441
                }
            }
        }
    }
]